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Abstract 
 
Alzheimer’s disease (AD), the most prevalent type of dementia, is a condition that 
leads to a progressive and irreversible deterioration of predominantly cortical functions. 
AD is characterized by loss of mental faculties, memory impairment, spatial and 
temporal disorientation, confusion and reasoning difficulties. The clinical signs of AD 
occur in parallel or are even preceded by intra or extracellular abnormal accumulation 
of amyloid beta (Aβ) deposits, Aβ toxic oligomers and τ protein neurofibrillary tangles in 
brain tissue. For this reason, molecular imaging studies with radiotracers that target Aβ 
can provide an important tool not only to detect the onset of the disease but also to 
assess the potential of new therapeutic approaches. Carbon-11 labelled Pittsburgh 
Compound B ([11C]PiB) binds in vivo to Aβ and is nowadays established in literature as 
the reference radiotracer for AD due to its higher sensitivity and good specificity for 
earlier detection of the disease. 
The aim of this work was to optimize a simple, rapid and fully automated preparation 
of [11C]PiB based on the captive solvent method. Starting from [11C]CO2 produced in a 
cyclotron through the 14N(p,α)11C nuclear reaction, a final sterile, non-pyrogenic saline 
solution of [11C]PiB was produced with high quality and reproducibility using a series of 
automated modules. 
The specific activity of the [11C]PiB produced was 27.6±4.1 GBq/µmol and 
radiochemical purity was always above 98%. Residual ethanol and acetonitrile in the 
solution were controlled using gas chromatography. pH, radionuclidic purity and half-life 
were all within their pharmacopoeia values. 
 
Keywords: [11C]Pittsburgh Compound B; [11C]methyl triflate; captive solvent method; 
Alzheimer’s disease. 
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Resumo 
 
A doença de Alzheimer (AD), o tipo mais prevalente de demência, conduz a uma 
deterioração progressiva e irreversível de funções predominantemente corticais. A AD 
caracteriza–se por perda das faculdades mentais, perturbações da memória, 
desorientação espacial e temporal, confusão e problemas de raciocínio. Os sinais 
clínicos de AD ocorrem em paralelo, ou são mesmo precedidos, de depósitos 
anómalos, intra ou extracelulares, de placas β-amilóides (Aβ) e emaranhados 
neurofibrilares de proteína τ no tecido cerebral. Por este motivo, os estudos de 
imagiologia molecular utilizando radiotraçadores com afinidade para os depósitos de 
Aβ são uma ferramenta indispensável no diagnóstico precoce das demências, na 
avaliação da resposta a novas terapêuticas e no auxílio ao desenvolvimento de 
terapias de última geração. O Composto B de Pittsburgh marcado com carbono-11 
([11C]PiB) liga-se in vivo aos depósitos de Aβ e está actualmente bem estabelecido na 
literatura como o radiotraçador de referência para AD devido à sua elevada 
sensibilidade e boa especificidade na detecção precoce desta demência. 
O objectivo deste trabalho foi de, partindo do [11C]CO2 produzido em ciclotrão através 
da reacção nuclear 14N(p,α)11C, optimizar um método automático, rápido e simplificado 
de preparação de uma solução estéril e apirogénica de [11C]PiB baseado no método 
de captura de solvente. 
A actividade específica obtida foi de cerca de 27.6±4.1 GBq/µmol e a pureza 
radioquímica esteve sempre acima dos 98%. Os níveis residuais de etanol e 
acetonitrilo foram controlados por cromatografia gasosa. O pH, a pureza radionuclídica 
e o período de semi-desintegração estavam todos dentro dos respectivos valores de 
referência. 
 
Palavras-chave: Composto B de Pittsburgh; triflato de [11C]metilo; metilação em 
loop; Doença de Alzheimer. 
 
  
  
  
 
ix 
 
List of abreviations 
 
AD – Alzheimer’s disease 
Ah – Ampere 
APP – Amyloid precursor protein 
Aβ – Amyloid beta 
BBB – Blood-brain barrier 
BPT – Bubble point test 
Bq – Becquerel 
BTA – Benzothiazole 
cGRPP – Current Good Radiopharmacy Practices 
Ci – Curie 
CT – Computed Tomography 
DC – Decay corrected 
DMF – Dimethylformamide 
DMSO – Dimethyl sulfoxide 
ESTeSL – Escola Superior de Tecnologia da Saúde (Lisbon Higher Scool of Health 
Technology) 
EU – Endotoxyns units 
FDG – Fluorodeoxyglucose 
FID – Flame ionization detector 
g – Gram 
GC – Gas chromatography 
GLP – Good Laboratory Practices 
GMP – Good Manufacturing Practices 
HPLC – High Pressure Liquid Chromatography 
i.v. – Intravenous 
ICNAS – Instituto de Ciências Nucleares Aplicada à Saúde (Institute for Nuclear 
Sciences Applied to Health) 
l – Liter 
  
  
  
 
x 
 
LAL – Limulus amebocyte lysate 
LD – Lethal dosis 
m – Meter 
M – Molar 
MCI – Mild cognitive impairment 
Me – Methyl 
MEK – Methyl ethyl ketone 
MeV – Mega electron-volt 
min – Minute 
MM – Molecular mass 
MOMO – Methoxymethyl 
MRI – Magnetic Resonance Imaging 
N – Normal 
OECD – Organization for Economic Cooperation and Development 
PET – Positron Emission Tomography 
Ph. Eur. – European Pharmacopoeia 
PiB – Pittsburgh Compound B 
ppm – Particles per million 
Rt – Retention time 
SA – Specific activity 
SN – Nucleophilic substitution 
SPE – Solid Phase Extraction 
SPECT – Single Photon Emission Computed Tomography 
Tf - Triflate 
THF – Tetrahydrofuran 
UV – Ultraviolet 
WFI – Water for injections 
 
  
  
  
 
xi 
 
Table of contents 
 
Acknowledgements ...................................................................................................... iii 
Abstract .......................................................................................................................... v 
Resumo ....................................................................................................................... vii 
List of abreviations ........................................................................................................ ix 
Table of contents .......................................................................................................... xi 
List of tables ................................................................................................................. xiii 
List of figures ............................................................................................................... xv 
1. Introduction ......................................................................................................... 1 
2. Literature review ................................................................................................. 3 
2.1 Molecular mechanisms of Alzheimer’s disease ................................................... 4 
2.2 Molecular Imaging in Alzheimer's disease ........................................................... 7 
2.2.1 [11C]PiB in the differentiation of Alzheimer's disease .................................. 11 
2.3 Synthesis of short lived PET radiotracers .......................................................... 13 
2.3.1. Carbon-11 radiochemistry ......................................................................... 16 
2.3.2 Pittsburgh Compound B radiosynthesis ...................................................... 20 
3. Justification of the project ............................................................................... 23 
4. Methodology ...................................................................................................... 25 
4.1 Instruments and materials ................................................................................. 26 
4.2 Experimental procedures .................................................................................. 27 
4.2.1 Optimization of the chromatographic conditions ......................................... 28 
4.2.2 Production of [11C]CH3I and [
11C]CH3OTf .................................................... 28 
4.2.3 Production of [11C]PiB in a captive solvent loop .......................................... 31 
4.2.4 Purification and reformulation of the final product ....................................... 32 
4.2.5 Quality control ............................................................................................ 33 
5. Results and discussion .................................................................................... 35 
5.1 Chromatographic system .................................................................................. 35 
5.2 Synthesis of [11C]CH3I and conversion into [
11C]CH3OTf ................................... 38 
5.3 The reaction by the captive solvent method ...................................................... 43 
5.4 Final purified saline solution of [11C]PiB ............................................................. 48 
5.5 Assurance of the final product quality ................................................................ 51 
6. Final considerations ......................................................................................... 57 
7. References ......................................................................................................... 61 
  
  
  
  
 
xiii 
 
 List of tables 
 
Table 2.1. Main radiotracers for neuroimaging with PET and SPECT. .......................... 8 
Table 2.2. Features of most commonly used PET radionuclides. ............................... 13 
Table 5.1. LiAlH4 volume influence in [
11C]CO2 trap and [
11C]CH3I production. ........... 40 
Table 5.2. Precursor dilution influence in [11C]PiB reaction yield and specific activity.. 46 
Table 5.3. Reaction time influence in [11C]PiB production yield and specific activity. .. 47 
Table 5.4. Optimal [11C]PiB reaction conditions and comparison with several authors.47 
Table 5.5. Results obtained with [11C]PiB radiolabellings. ........................................... 52 
 
  
  
  
 
xv 
 
 List of figures 
  
Figure 2.1. The amyloid cascade hypothesis. .............................................................. 5 
Figure 2.2. Flow chart for evaluation of PET brain studies.......................................... 10 
Figure 2.3. Progression of Aβ deposits in AD. ............................................................ 12 
Figure 2.4. Pathway from cyclotron production to final use of a PET tracer. ............... 14 
Figure 2.5. Radioactive precursors for 11C synthesis. ................................................. 17 
Figure 2.6. Scheme of loop injector as a solid phase reaction system. ....................... 19 
Figure 2.7. Structure of thioflavin T analogues and radiolabelling reactions. .............. 21 
Figure 4.1. Scheme of the adopted [11C]PiB synthesis process. ................................. 25 
Figure 4.2. Diagram of the interactions between the devices involved. ...................... 26 
Figure 4.3. Schematic diagram of the automated 11C radiolabelling system used. ..... 28 
Figure 4.4. Columns used on the synthesis of [11C]CH3OTf........................................ 31 
Figure 5.1. Analytical HPLC of cold standards mixture. .............................................. 37 
Figure 5.2. Semi-preparative HPLC of cold standards mixture. .................................. 37 
Figure 5.3. Reference curve for the calculation of PiB concentration. ......................... 38 
Figure 5.4. Synthesis of [11C]CH3I by the “wet method”. ............................................. 39 
Figure 5.5. [11C]CH3I production profile. ..................................................................... 41 
Figure 5.6. Semi-preparative HPLC of [11C]PiB and main radiochemical impurities. ... 42 
Figure 5.7. Optimum profile for [11C]CH3OTf trapping in the loop................................ 44 
Figure 5.8. Semi-preparative HPLC of [11C]PiB methylation using DMSO. ................. 45 
Figure 5.9. Semi-preparative HPLC for purification of [11C]PiB. .................................. 48 
Figure 5.10. SPE C18 cartridge profile during [11C]PiB purification. ............................ 49 
Figure 5.11. Gas chromatography of the final [11C]PiB i.v. solution. ........................... 53 
Figure 5.12. Analytical HPLC of [11C]PiB solution before purification. ......................... 54 
Figure 5.13. Analytical HPLC of the final [11C]PiB i.v. solution. ................................... 54 
Figure 5.14. [11C]PiB final solution stability over time. ................................................ 55 
Figure 6.1. [11C]PiB amyloid binding to the brain of an AD and healthy cases. ........... 59 
 
  
  
  
 
1 
 
1. Introduction 
 
This dissertation is submitted for the fulfilment of the requirements for the Master’s 
degree in Nuclear Medicine, specialization in Radiopharmacy, by the Lisbon Higher 
School of Health Technology (ESTeSL). The work was conducted at the Institute for 
Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, with the overall 
aim of establishing an automated and reproducible method for radiolabelling - by the 
captive solvent method -, purification and reformulation of [11C]Pittsburgh Compound B 
([11C]PiB) using a system composed by commercial synthesis modules (Bioscan Inc. 
Washington DC, USA) in order to obtain a sterile and pyrogen-free injectable solution. 
Originally developed in 2000 at the University of Pittsburgh, [11C]PiB is a 
benzothiazole compound, analogue of thioflavin T, with known affinity for amyloid beta 
(Aβ) deposits. The compound is labelled with the positron emitter carbon-11 ([11C]) for 
the early diagnosis of Alzheimer’s disease (AD) with Positron Emission Tomography 
(PET). PET is a non-invasive Nuclear Medicine diagnostic technique which can 
reconstruct functional images through information generated from the two anti-parallel 
511 keV γ photons emitted by annihilation of an emitted positron with an electron of the 
surrounding material. 
AD is manifested by a progressive deterioration of mental and intellectual faculties 
that interfere with the ability to function normally in society. It is also characterized by a 
deterioration of both long and short term memories and a disintegration of the 
personality due to changes in the discernment and judgment. Being associated with 
advancing age and considering the world demographic development for the coming 
decades, that predicts a dramatic increase in the population aged over 65 years, it is 
expected that AD will become a major health concern in the coming years. It is, 
therefore, of great importance the development of diagnostic techniques that target the 
Aβ plaques, the hallmark of this dementia. Currently there is no clinical or laboratory 
exam that can, by itself, definitively diagnose AD in life. The only way to do this is 
through direct observation of the presence of amyloid plaques in cerebral homogenates 
after autopsy. Nevertheless, several studies published in the literature demonstrate a 
strong quantitative correlation between the presence of these deposits and in vivo 
uptake of [11C]PiB. This has consolidated this radiotracer as a powerful tool with high 
sensitivity and specificity for validating treatments for neurodegenerative diseases and 
opens a window to a new era of preventive medicine in dementia. Using this tracer it 
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will be possible to test new drugs at an early stage of the disease, even before the 
symptoms begin to manifest. 
Owing to its physicochemical characteristics, the use of radiotracers labelled with 11C 
in routine PET scans requires the presence in loco of a suitable production facility. The 
only centre in Portugal that hosts a biomedical cyclotron, a radiochemistry laboratory 
and a PET diagnostic unit is ICNAS. Considering that pre-validated kits for routine 
production of [11C]PiB are not available, each production facility has to develop an 
automated synthesis, purification and dispensing process based on multi-purpose 
hardware available. The development of such process is the subject of this work and 
the [11C]PiB produced is expected to make a strong impact on the diagnosis and 
clinical management of AD in Portugal and provide an important tool for basic and 
clinical for R&D in this area. 
The work plan included a revision of the state-of-the-art in the field including 
molecular basis of AD and its diagnosis as well as major challenges faced by the 
radiolabelling of products with 11C and its automation. Technical challenges to 
overcome included the used of automated modules and the understanding of 
electromechanical processes necessary for its operation and correct maintenance. The 
main experimental work was then the implementation and optimization of the [11C]PiB 
synthesis, purification and reformulation specially in regards to the main parameters of 
purity (chemical and radiochemical), yield and specific activity (SA) of the final product. 
Following the so called “wet method” the process starts from cyclotron produced 
carbon dioxide ([11C]CO2), obtained by a 
14N(p,α)11C nuclear reaction through the 
irradiation of a gaseous nitrogen target with 0.5% of O2. Subsequently, [
11C]CO2 
produced will be converted on an automated system (MeI-PlusTM, Bioscan Inc.) to 
[11C]methyl iodide ([11C]CH3I) and [
11C]methyl triflate ([11C]CH3OTf). The reaction then 
takes place by the “captive solvent” methylation loop technique (AutoLoopTM, Bioscan 
Inc.) and, after semi-preparative High Pressure Liquid Chromatography (HPLC) 
purification, final reformulation is done (ReFORM-PlusTM, Bioscan Inc.) to produce 
[11C]PiB in a suitable solution for in vivo human studies. 
Due to short half-life of 11C (20.4 minutes) the greatest challenge is the promptitude 
by which the radiotracer must be synthesized, purified and quality controlled before 
administration is carry out. It is, therefore, very important that the entire process of 
synthesis and evaluation of the radiopharmaceutical is as fast as possible. This is a 
critical factor that has to be taken into account in all steps of the optimization process. 
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2. Literature review 
 
It was in the 1960s that various socio-economic studies began to draw attention to the 
demographic phenomenon of aging. Studies of the Organization for Economic 
Cooperation and Development (OECD) estimate that in 2050 one fifth of the world 
population will have more than 65 years(1). As a first approach to this problem we can 
expect that this aging will be based on an increase of average life expectancy which 
announces a better improvement of medical techniques and an enlargement to the 
access to specialized platforms that ensures a continuum health care to the population, 
but on the other hand this factor will increase the risk for developing chronic and 
degenerative complications, of which one of the most important group are 
neurodegenerative diseases or dementias. 
In 2011 the Alzheimer's disease International estimated a total of 36 million people 
suffering from dementia worldwide, representing an economic cost exceeding 1% of 
the world total Gross Domestic Product. This number is expected to rise to 66 million 
by 2030 and 115 million by 2050(2). A project from European Collaboration on Dementia 
group estimated about 153.000 persons suffering from dementia in Portugal, of which 
90.000 have AD. This numbers are also expected to double in the next 20 years. 
AD is the most prevalent type of dementia, i.e., a disease that leads to progressive 
and irreversible deterioration of predominantly cortical functions, and is characterized 
by loss of mental faculties, memory impairment, spatial and temporal disorientation, 
confusion and reasoning problems(3). These symptoms worsen as the 
neurodegenerative process is intensified and the communication between neurons 
becomes deficient which culminates in behaviour and personality changes and inability 
to complete routine activities. The visible signs of AD occur in parallel or are even 
preceded by intra or extracellular abnormal accumulation of Aβ deposits, Aβ toxic 
oligomers and τ proteins neurofibrillary tangles in nerve cells(4). The study of these 
changes at a molecular level became a strong line of scientific research in order to lead 
to a better understanding of the underlying mechanisms of this dementia, to identify 
new biomarkers and to develop resources to support their diagnosis at an earlier time, 
a strategy that has the potential to increase the efficiency of the therapeutics. 
For this reason, molecular imaging studies with radiotracers that target Aβ can 
provide an important tool not only to detect the onset of the disease but also to assess 
the potential of new therapeutic approaches. 
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2.1 Molecular mechanisms of Alzheimer’s disease 
Cerebral regions involved in learning, attention and memory processes, including 
frontal and temporal lobes, are anatomically diminished in AD patients due to neuronal 
death and synaptic degeneration(4). Other modifications, such as a decrease in 
astrocytes, proliferation of abnormal clusters of microglial cells (that produce a number 
of various neurotoxic substances) and a reduction in acetylcholinesterase levels and 
cholinergic neuroreceptors, associated with brain regions involved in processes related 
with learning and memory, were also associated to this dementia(5-7). However, since 
other dementias share many of the symptoms and neurological alterations of AD, such 
as frontotemporal, Lewy body or multi-infarct, its diagnosis was only definitely closed 
when Aβ plaques and neurofibrillary tangles were identified in post-mortem brain 
tissue(8). These two histopathological hallmarks of AD are directly related to the 
progressive loss of inter-neuronal communications as firstly described in early XX 
century by German neurologist Alois Alzheimer after an anatomopathological 
examination of the brain of a patient who presented abnormal behaviour(9). 
Nowadays it is known that Aβ peptides derive from the amyloid precursor protein 
(APP) that plays an important role on neuronal development and in the adherence of 
neurons to the cellular matrix. APP is transported through the axons to the synaptic 
terminals where is accumulated at high concentrations. Throughout this transport it 
suffers several proteolytic cleavages originating Aβ peptides. Normally these Aβ 
peptides are physiologically removed from brain parenchyma but, in AD, several 
mutations or failures in the clearance mechanisms are thought to exist (e.g., non 
activated microglia) that result in an abnormal progressive accumulation of Aβ 
oligomers(7, 10). The neurotoxicity of these protein deposits with β-sheet structure were 
already verified by in vitro studies and probably are the primarily cause that leads to the 
formation of amyloid plaques which originate modifications in synaptic plasticity and 
neuronal integrity(11-13). This cascade culminates in neurodegeneration through 
processes such as oxidative stress, disturbances in energetic metabolism due to 
deterioration of glucose transport mechanisms, modifications in cellular calcium 
homeostasis or adulteration of synaptic proteins such as τ protein(14). 
As a result of the changes produced during the amyloid cascade, and in addition  to 
the  Aβ plaques,  neurofibrillary  tangles  of  accumulated  τ  proteins  are also formed 
(see Figure 2.1). These soluble proteins are usually responsible for tubulin 
polymerization and the aggregation of microtubules, an essential process in the 
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formation of the cytoskeleton(15-17). Nevertheless, when in the form of neurofibrillary 
tangles, τ proteins become insoluble, phosphorylated and unstable decreasing their 
affinity to microtubules. This originates cytoskeleton rupture and, consequently, 
neuronal destruction(18, 19). The mechanism that triggers these reactions it is not yet 
totally known but there are evidences who suggests that the deposition of Aβ oligomers 
adulterates the activity of some kinases (FAK1, PTK2, CDK5, GSK3α) that will promote 
the abnormal phosphorylation of τ protein(10). 
About 70% of suspected AD cases are attributed to genetic causes. Dominant 
mutations in genes that encode APP, presenilin or apolipoprotein E are among the 
most frequently found risk factors(20). Other genes presenting a risk for AD still remain 
the subject of numerous studies(21). Mutations in τ proteins are mainly responsible for 
frontotemporal dementia and corticobasal degenerations and are not an AD risk 
factor(22). Nevertheless, their study remains important because, although the presence 
of Aβ plaques is the hallmark of AD, the severity of the disease is more closely related 
with the presence of the neurofibrillary tangles of τ proteins(23). 
 
 
Figure 2.1. The amyloid cascade hypothesis. 
 
There is no single medical test that can unequivocally diagnose AD in life. Therefore, 
the diagnosis is performed by a multidisciplinary approach using neuropsychological 
tests, blood and cerebrospinal fluid analysis, electroencephalograms and structural 
neuroimaging techniques through a process of exclusion of other pathologies that could 
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have similar signs and symptoms(24). Within the neuroimaging techniques, Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) are, in general, routinely 
used in the study of patients with suspected dementia to exclude other clinical causes 
such as  tumours, cerebral haematomas, hydrocephaly or cerebrovascular diseases(25). 
The advantage of CT scanning is debatable since its efficiency to reveal abnormalities 
that were not described in previous clinical examinations is only between 1% and 
10%(26, 27). Due to its increased specificity, MRI became the reference imaging 
technique to reveal atrophies in hippocampus, posterior cerebral cortex and in the 
intermediate region between temporal and parietal lobes in patients with suspected 
AD(28). In the absence of a curative or preventive treatment for AD, an early diagnosis 
allows a non-pharmacological and pharmacological intervention more effective in 
relieving symptoms and preserving physical skills, with real gains in quality of life. For 
this reason it is important to diagnose AD at an early stage when no anatomic effects 
are present yet. So, an imaging technique with focus on the very first molecular 
changes will be capable to improve prophylaxis and be a valuable resource on the 
search for new drugs capable to stop or slow down these processes. 
The diagnostic procedures in Nuclear Medicine by Single Photon Emission Computed 
Tomography (SPECT) and especially PET, which in the last decade has been focus of 
major interest and scientific development associated with the increase of available 
radiotracers, allow in vivo imaging of brain activity by mapping blood flow or glucose 
metabolism, enable the study of cerebral biochemistry and neurotransmitters and 
provide differential diagnosis for some dementias(29, 30). 
Molecular imaging with PET associated with suitable radiotracers provides valuable 
information about many aspects of the neurobiology of AD and has potential application 
in early diagnosis and to monitor therapeutic efficiency. Until recently, the most used 
diagnostic criteria for AD using functional imaging has been the identification of spots 
with reduced glucose metabolism in parieto-temporal cerebral areas. This studies use 
[18F]fluorodeoxyglucose ([18F]FDG) and have a sensibility and specificity of 86%(31). 
However the development of new specific radiotracers for Aβ deposits, simultaneously 
with results that showed a strong quantitative correlation between in vivo uptake and 
the presence of these Aβ plaques detected post-mortem in brain tissue, has increased 
the interest in their clinical use for a faster and more accurate diagnosis and 
differentiation of dementias. 
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2.2 Molecular Imaging in Alzheimer's disease 
Nuclear Medicine can be defined as the use of radioisotopes for the diagnosis, 
treatment and study of diseases, being one of the most relevant techniques in the 
emerging field of Molecular Imaging which allows the visualization, characterization and 
quantification of the molecular scale cellular and biochemical processes in living 
systems(32, 33). The major challenge of brain molecular imaging is to develop 
radiotracers that penetrate in the highly selective blood-brain barrier (BBB). For this, 
they should not have very high molecular weight (less than 600 Dalton), be neutral or 
have a weak ionization at physiological pH and present low percentage of plasma 
protein binding. It is also important that they have a high SA and are not metabolized, 
during the time of the imaging acquisition, to active compounds that could mask the 
specific signal of the parent compound(34-36). To have a radiotracer that effectively cross 
the BBB it is necessary to reach a compromise between lipophilicity and hydrophilicity 
since if it is too lipophilic will tend to be trapped in the adipose tissues, to bind more 
tightly to plasma proteins, which will decrease the interaction with receptors, and to be 
slightly soluble in aqueous phases, which alters the desired biodistribution. By the other 
way, if the radiotracer is very hydrophilic it may not be able to pass through 
membranes, including BBB, increasing the susceptibility of being rapidly excreted 
before reaching the desired target(37). 
In general we can consider, in the clinical setting, four classes of radiotracers for 
functional brain imaging. Those include the study of blood flow, glucose metabolism, 
receptor mapping and the characteristic biomarkers of a particular dementia(33). 
Currently there is a growing availability of radiolabelled molecules with specificity to 
picomolar scale neuronal mechanisms. These are used in pre-clinical studies and in 
research with the aim of reaching an increasingly early diagnosis of dementias, to 
evaluate the response to new therapies and to help in the development of last 
generation psychoactive drugs. Table 2.1 lists some of the most used SPECT and PET 
radiotracers for neurologic and psychiatric nuclear imaging studies(29, 30, 33, 38). 
Cerebral blood flow is directly related to the supply of metabolic nutrients to neurons. 
For this reason, it is important to study this factor to map which brain regions show a 
deficit of perfusion and correlate them with the symptoms presented by patients with 
dementia. 99mTc-ECD and 99mTC-HMPAO are two agents that diffuse to cerebral tissue 
and suffer an intracellular retention proportional to blood flow. This phenomenon can be 
correlated with AD since cerebral perfusion has different patterns depending on the 
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type of dementia(29, 39). By studying its uptake in the occipital and parietal cortices, 
[123I]iodoamphetamine has also been used for the differential diagnosis between AD 
and multi-infarct dementia(40). The use of SPECT radiotracers which allow the study of 
the BBB integrity, such as [67Ga] gallium citrate, has also proved to be important in the 
understanding of AD since there is some evidence that relate the destruction of BBB 
with an increased cerebral deposition of Aβ oligomers(41). 
 
 Table 2.1. Main radiotracers for neuroimaging with PET and SPECT 
 
Biological 
Process 
Target 
Radiotracers 
SPECT PET 
Cerebral blood flow  99mTc-HMPAO; 99mTC-ECD; 
[123I]iodoamphetamine 
[15O]H2O 
BBB integrity  99mTc-glucoheptonate; 
[67Ga]gallium citrate; 99mTcO4
-; 
 
Glucose 
metabolism 
Hexokinase and 
glucose transporters 
 [18F]FDG 
Neurotransmitters Dopaminergic system [123I] β-CIT; 99mTc-TRODAT; 
[123I]IBZM; [123I]altropane 
[18F]DOPA; [18F]FP-CIT; 
[11C]raclopride; [11C]DTBZ; 
[18F] β-CFT; [11C]SCH-23390 
 Cholinergic system [123I]A-85380 [18F]FP-TZTP; [11C]nicotine; 
[11C]MP4A; [11C]PMP; 
[8F]A-85380 
 Serotonergic system [123I]ADAM [18F]MPPF; [18F]altanserin 
[18F]setoperone; [11C]DASP 
 GABAergic system [123I]iomazenil [18F/11C]flumazenil 
 Opioid system  [11C]carfentanil;  [18F]ciclofoxy 
Biomarkers of 
dementia 
Aβ deposits  [18F]AV-45; [11C]SB-13; 
[11C]PiB; [18F]BAY-94-9172; 
[11C]AZD-2184 
 τ protein  [
18F]FDDNP 
 Microglia  [11C]PK11195;  [11C]DAA1106 
 Astrocytes  [11C]DED 
 
Regarding PET imaging, [15O]H2O can be considered the brain perfusion agent par 
excellence because its retention time and clearance are directly proportional to blood 
flow in a given tissue, independently of its metabolism and possible pathophysiological 
changes(42). [18F]FDG studies of cerebral glucose metabolism, which allow inferences 
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about synaptic activity, has shown great importance in the separation of the various 
dementias since the cognitive and functional changes, and consequently the brain 
regions affected, are different(43, 44). The cases of patients with AD normally 
demonstrated a classical pattern of bilateral glucose hypometabolism in the 
parieto-temporal lobes, which does not happen in most other dementias(45). 
Looking at Table 2.1 it is clear that as the biological processes under study become 
more specific the availability of SPECT tracers diminishes. This is due to the fact that 
their chemistry is essentially based on complexes of transition and post-transition 
metals with high atomic number and no relevance in living systems, making them 
highly reactive and bioaccumulable. It is, therefore, difficult to synthesize radiotracers 
with high specificity for biological processes at a nano or picomolar scale. One attempt 
to solve this problem is through the use of iodine radioisotopes since they can be easily 
introduced on the tyrosine, histidine or histamine residues although, on the other hand, 
they also have the disadvantage of being able to cause a significant increase on the 
lipophilicity of the biomolecules(33, 46). Therefore, the alternative is to use PET 
radiotracers that can be labelled with radioisotopes from the most prevalent elements in 
organic molecules which allow the labelling of, virtually, any molecule without losing its 
biological activity. The development of PET technology associated with the availability 
of different radiotracers increased the sensitivity in clinical evaluation and differentiation 
of dementias (see Figure 2.2). Up to this point dementias were often erroneously 
confused with normal cognitive decline inherent to aging and failures in its diagnosis 
reached values in the order of 40% to 90%(47). In parallel to the technological advances 
of the radiation detection systems and to the development of new hybrid systems, in 
particular PET/MRI that adds a high spatial resolution technique (MRI) to the high 
sensitivity of PET, the ability to synthesized radiotracers with increasing specificity for 
the characteristic molecular targets of each dementia made possible a more assertive 
diagnostic. 
Cholinergic receptors and amyloid plaques are, as mentioned above, two of the major 
molecular targets in Alzheimer's disease so there has been a growing interest in the 
synthesis of biospecific radiotracers to target them. Studies with [11C]nicotine and 
[18F]A-85380 mapped nicotinic cholinergic receptors of neuroglia and concluded that 
their levels are dramatically reduced in patients with AD(48, 49). Another way to study 
indirectly the cholinergic receptors is by the acetylcholinesterase activity as this 
enzyme is responsible for the degradation of acetylcholine in the cerebral cortex. If 
cholinergic receptors are reduced in AD then it is expected that the neurotransmitter 
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acetylcholine is also diminished, which means a decline in the acetylcholinesterase 
activity such as revealed by studies with [11C]PMP and [11C]MP4A(5, 50). 
 
 
 Figure 2.2. Flow chart for evaluation of PET brain studies. (Silverman
(51)
) 
 
[18F]FDDNP was the first PET radiotracer that allowed in vivo imaging of AD by 
binding to τ proteins in neurofibrillary tangles(52). Despite the difficulties in synthesizing 
radiotracers with affinity for the amyloid plaque mostly due to ignorance of all AD 
mechanisms, some molecules such as [11C]SB-13 and [11C]PK11195 were synthesized 
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later and proved to be clinically interesting and helped to better understand the stages 
of amyloid cascade(30, 53). However, it was only with the development of [11C]PiB, a 
benzothiazole derived from thioflavin T that binds in vivo to Aβ deposits in a manner 
that is strongly correlated with the amount of Aβ deposits observed post-mortem in 
brain tissue of AD patients, that became possible to realize PET quantification studies 
of senile plaques(54-57). Although having the disadvantage of the short half-life of 11C 
that prevents its distribution to Molecular Imaging centres without a cyclotron, [11C]PiB 
is now well established in the literature as the reference radiotracer for AD due to its 
high sensitivity (89%) and very good specificity (83%) for earlier detection of the 
disease(58-61). The exact way by which [11C]PiB binds to the Aβ plaques is not 
completely understood but in vitro studies showed specific binding only to extracellular 
and intravascular deposits of Aβ oligomers and not to the unbound and free peptides(54, 
57, 62). Intravenous (i.v.) administration of low nanomolar concentrations is enough to 
obtain a satisfactory biodistribution of the radiotracer in order to have sufficient affinity 
for the Aβ plaques without binding to other aggregates such as neurofibrillary tangles or 
α-synuclein and ubiquitin in Lewy bodies dementia, while maintaining a rapid clearance 
of normal brain tissue(56, 63, 64). This has consolidated [11C]PiB as not only the gold 
standard for in vivo quantification of Aβ deposits in PET diagnosis of AD but also as an 
important tool to establish the relationship between Aβ affected areas and functional or 
structural changes which enables, for example, an appropriate selection of patients for 
new anti-amyloid therapies(64). 
The pharmaceutical industry has estimated a potential market of around 500 million 
dollars a year, in the coming decades, for biomarkers and molecular probes designed 
for the diagnosis of AD. There are already some fluorine-18 based radiotracers in 
phases II and III of clinical trials or in the process of market authorization such as 
3’-[18F]-PiB (GE Healthcare), [18F]BAY-94-9172 (Bayer) and [18F]AV-45 (Lilly 
pharmaceutical) which have proved to be promising in the differentiation of patients 
with AD(58, 65). However [11C]PiB still remains the benchmark for the development of 
these new tracers. 
 
2.2.1 [11C]PiB in the differentiation of Alzheimer's disease 
By having a high affinity for Aβ deposits (Kd = 1.4 nM), easy access through the BBB 
and low toxicity, [11C]PiB is currently the radiotracer with greater specificity and 
sensitivity for early detection of Aβ plaques and vascular amyloid deposits in the 
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brain(54, 66). A brain protocol for studies with [11C]PiB must respect the same general 
contraindications and previous preparation of the patient that routine scans with 
[18F]FDG(67). Even if brain uptake of [11C]PiB is not dependent on the surrounding 
conditions it should always be taken into account patient rest in a controlled, 
comfortable and quiet environment and the use of anaesthetics or sedatives equated 
only in extreme cases(68). In patients with suspected AD a prominent uptake of [11C]PiB 
is expected in frontal and parietal lobes and a reduction in temporal lobes(56). [11C]PiB 
has a non-specific affinity for the cerebral white matter which has been attributed to a 
decrease of the radiotracer kinetic in this region(69). However its effectiveness in 
diagnosis of AD is approximately 90%(70) and the cerebral retention rate about two 
times higher than in normal patients(71). 
Longitudinal studies have shown that the pattern of brain uptake of [18F]FDG and 
[11C]PiB differs over time and that the amyloid deposits appear to occur before 
cognitive symptoms and, perhaps, even before there were a minimum impairment of 
memory(72). This way it can be possible to discriminate, through [11C]PiB studies, 
different stages of AD according to Aβ deposits localization and concentration within 
the cerebral cortex(73) (see Figure 2.3). The possibility of Aβ deposits quantification 
through [11C]PiB brain uptake is a major advantage that can be used to differentiate 
patients   with   AD   or   mild   cognitive   impairment   (MCI)   from   healthy   subjects 
(see  Figure 2.3)(51, 64, 66, 74, 75). The uptake pattern of [11C]PiB in a PET scan also 
demonstrated some potential in differentiating between AD and Lewy bodies dementia, 
frontotemporal dementia and Parkinson's, having this last one, an amplification of the 
radiotracer retention in the mesencephalon(30). 
 
 
 Figure 2.3. Progression of Aβ deposits in AD. (Adapted from Nordberg
(73)
 and Langstrom
(75)
) 
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Comparative PET scans in patients with MCI, that due to its progression rate for AD of 
80% in 6 years is considered the ideal etiological stage to evaluate an early diagnosis 
of AD, found that [11C]PiB has greater sensitivity and specificity than [18F]FDG in 
anticipating ongoing brain function atrophy(76, 77). 
 
2.3 Synthesis of short lived PET radiotracers 
Fluorine-18 (18F), carbon-11 (11C), nitrogen-13 (13N) and oxygen-15 (15O) are the most 
frequently used radionuclides in PET (see Table 2.2). This is, in part, due to the fact 
that they can be produced efficiently in a medical cyclotron and have a radioactive 
decay almost exclusively by β+ emission but especially because they are isotopes of 
elements with low atomic mass that are highly prevalent in all organic molecules. This 
makes them easy to introduce directly in any molecule of interest without modifying 
significantly its biological activity. The production of radioisotopes requires the 
existence of a particle accelerator capable to generate proton or deuteron beams with 
sufficient energy that can be directed to a specific target material suitable for the 
production of 11C, 13N, 15O, 18F or other. 
 
 Table 2.2. Features of most commonly used PET radionuclides
(78) 
Radionuclide 
t1/2 
(minutes) 
Nuclear 
reaction 
Target 
Primary 
precursors 
Decay 
product 
15
O 2.04 
14
N(d,n)
15
O N2(+O2) [
15
O]O2 
15
N 
13
N 9,97 
16
O(p, α)
13
N H2O 
H2O+EtOH 
[
13
N]NO2/3 
[
13
N]NH3 
13
C 
11
C 20.4 
14
N(p,α)
11
C N2(+O2) 
N2(+H2) 
[
11
C]CO2 
[
11
C]CH4 11B 
18
F 109.8 20Ne(d,α)
18
F 
18
O(p,n)
18
F 
Ne(+F2) 
[
18
O]H2O 
[
18
F]F2 
[
18
F]F
-
 
18
O 
 
The interest in these positron emitters increased in the 1970s when technological 
advances allowed the detection, in coincidence, of both γ photons that arise from the 
emission process enabling the production of images capable of reveal molecular 
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processes and interactions in vivo(79). These photons result from the annihilation of 
positrons (β+ particles) with electrons at the surrounding tissue generating two 
detectable anti-parallel 511 keV γ rays. The critical parameter regarding this 
radionuclides are their short half-lives (t1/2), which means that production, synthesis, 
quality  control  and  imaging  must  be  time  compatible  with  this  physical  property 
(see Figure 2.4). Due to the favourable t1/2, the only commercially available compounds 
are radiolabelled with 18F while the use of the other radionuclides is limited to facilities 
where cyclotron, radiochemistry labs and appropriate diagnostic equipment coexist(38). 
 
  
Figure 2.4. Pathway from cyclotron production to final use of a PET tracer. 
 
The synthesis of all PET radiotracers begins from simple primary radioactive 
precursors resulting from reactions that occur in the particular environment of the 
cyclotron target between high energy particle beams (usually protons and neutrons) 
and selected stable nuclei. In these favourable conditions it is possible to overcome the 
barrier of activation energy and produce, by a nuclear reaction, unstable nuclides in a 
chemical form that is frequently determined by the thermodynamics of each constituent, 
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which leads to very stable and unreactive molecules(79). From these primary precursors 
is often necessary to quickly synthesize other secondary ones with greater reactivity 
and which can be introduced, as late as possible, into more complex molecules, a 
process that is often followed by a purification step in order to isolate the final product. 
Radiolabelling reactions occur in the presence of nanomolar quantities of the 
radioisotope which means that there is a stoichiometric excess of the cold reagents. 
This promotes first order reactions kinetics and reduces the total synthesis time(78). 
The development of automatic and remotely controlled procedures for handling 
radioisotopes and the improvement of radiochemistry is essential to ensure maximum 
radiological protection and reproducibility, especially in cases where these procedures 
are routinely performed for clinical applications. 
The short t1/2 of 
13N and 15O does not allow synthesis with more than one step that 
typically requires time-consuming purification methods, so their application is usually 
limited to the incorporation into small molecules. Simpler chemical forms such as 
[15O]CO2, [
15O]H2O and [
13N]NH3 can be directly obtained from cyclotron and used in 
blood flow studies or be quickly converted into other products such as [15O]CO, 
[15O]n-butanol or [13N]cisplatin(78). The enzymatic synthesis of [13N]amino acids with 
high yield and purity and without loss of biochemical activity, is one of the most 
frequently used approaches to these radionuclides and allows, for example, the study 
of cellular proliferation or the evaluation of cardiac metabolism(80). 
Despite not being a common element in the structure of biomolecules, the proximity of 
Van der Waals radius with the one of atomic hydrogen, their similar covalent bond 
length with C and a convenient t1/2, made fluorine-18 the most widely used PET 
radionuclide(81). The chosen nuclear reaction in the cyclotron affects the chemical form 
([18F]F2 or [
18F]F-) and the nature (electrophilic or nucleophilic) of the obtained 18F which 
increases the possibility of radiofluorination of different molecules of interest. The 
electrophilic substitution allows the easy insertion of the radioactive fluorine in 
electronically rich structures (aromatic rings or alkenes) but, due to its high reactivity, 
reactions are not regioselective leading to a lower radiolabelling yield which requires a 
more complex chromatographic separation. This reactivity may be moderated by 
dilution with an inert gas and working at low temperatures but the reaction will always 
lead to products with low SA due to the production method of [18F]F2 that requires the 
addition of a small amount of cold fluorine (carrier) to prevent adsorption to the target. 
For avoiding these drawbacks, the nucleophilic substitution using [18F]F- is a preferable 
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and most common method for the preparation of the majority of PET radiotracers 
although, in some cases, it is necessary the introduction of prosthetic groups and the 
protection of more reactive positions in the target molecule(78). 
The introduction of a foreign element in the original chemical structure of a molecule, 
as often happens in the case of fluorination, may cause a change in biological 
properties. The presence of carbon atoms in all relevant biomolecules makes the 
radiolabelling with 11C the most attractive (except in molecules with long term 
biodistribution, e.g., proteins) and important method for the synthesis of PET 
radiotracers since it offers the possibility of labelling molecules without changing its 
chemical and biological characteristics. This factor is especially important in 
compounds for brain studies as the preservation of physicochemical characteristics is 
essential for the BBB permeability and for the affinity to specific molecular targets. 
With a t1/2 of approximately 20 minutes, the major challenge in the use of 
11C is the 
development of increasingly fast, reliable, versatile and automated radiosynthesis 
procedures starting from the less reactive primary precursors [11C]CO2 or [
11C]CH4. 
 
2.3.1. Carbon-11 radiochemistry 
The carbon atom is a transversal constituent of all biological molecules. For this 
reason, and due to the relative ease with which it can be incorporated into 
biomolecules of interest without significant loss of chemical properties and biological 
activity, 11C is one of the most commonly used radioisotopes in the synthesis of 
radiotracers. However, side reactions with atmospheric [12C]CO2 and a half-life of about 
20 minutes make the synthesis of 11C radiotracers with high SA a real challenge in 
radiochemistry. So, despite the fact that virtually all potentially interesting biomolecules 
can be labelled with 11C, this is far from being a linear process. 
Radiochemical reactions should occur as quickly as possible (typically a maximum of 
5 minutes) and present reasonable yields and low quantities of side products, so that 
the final product can be rapidly purified, usually by HPLC. The resulting radiotracer 
should have high chemical and radiochemical purity and has to be formulated to 
produce a sterile non-pyrogenic solution ready for i.v. administration. The whole 
process should not exceed the time corresponding to two 11C half-lives, i.e., 
approximately 40 minutes. Precursors for the most common 11C radiotracers are 
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commercially available and an intense activity of research has developed a wide variety 
of reactions for their radiolabelling(81). 
The production of 11C is made by cyclotron irradiation of a nitrogen gaseous target 
with protons according to the nuclear reaction 14N(p,α)11C. Depending on whether the 
irradiation is carried out in the presence of O2 (0.5-1%) or H2 (5-10%), 
11C is obtained in 
the chemical form of [11C]CO2 or [
11C]CH4 which, being species with low reactivity, 
require the synthesis of other more reactive (secondary) precursors (see Figure 2.5). 
The development of strategies for labelling with 11C using, for example, reactions with 
phosgene ([11C]COCl2), cyanide ([
11C]HCN), carbon dioxide ([11C]CO2) and carbonyl 
([11C]CO) increased the diversity of molecules containing this radionuclide that can be 
synthesized(82). However, [11C]CH3I is the most widely used secondary precursor since 
it is more versatile in alkylation reactions and it also has the advantage of being 
synthesized by different pathways. 
The synthesis by the so called “gas phase method” starts with [11C]CH4, obtained 
either directly from the cyclotron or by reducing [11C]CO2 through nickel catalysis. 
[11C]CH4 is then converted in [
11C]CH3I in the presence of iodine vapours at elevated 
temperature (approx. 700° C)(83). This pathway provides clear advantages for not using 
aggressive reagents and leads to higher SA of the final product (due to the low amount 
of [12C]CH4 in the air, approximately 1.6 ppm, in contrast to the 330 ppm of [
12C]CO2). 
Nevertheless, the greater ease of automation of the [11C]CH3I synthesis by the “wet 
method” with very efficient final yields, leading to bigger absolute quantities of 11C, 
makes this technique the most commonly used(82). 
 
 
Figure 2.5. Radioactive precursors for 
11
C synthesis. (Adapted from Scott
(84)
) 
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In the synthesis of [11C]CH3I by the “wet method”, [
11C]CO2 is reduced to 
[11C]methanol ([11C]CH3OH) in the presence of lithium aluminium tetrahydride (LiAlH4) 
in tetrahydrofuran (THF). After THF evaporation a hydrolysis by hydriodic acid (HI) is 
carried out followed by a distillation of the [11C]CH3I. All this process should occur in an 
inert atmosphere and under anhydrous nitrogen or helium flow in order to avoid 
[12C]CO2 in the reaction environment. In fact, contamination with atmospheric CO2 is 
the main problem in this method as it is also reduced with LiAlH4 (in competition with 
[11C]CO2) and will cause a dramatic reduction in the specific activity of [
11C]CH3I and, 
consequently, of the final alkylation product. 
Due to its simplicity, speed and to the fact that many biomolecules contain a 
methylamine, aniline or anisole pharmacophore, the most commonly pathway of 
methylation with 11C is by SN2 nucleophilic substitution. This reaction occurs from 
previously demethylated compounds containing primary amines, thiol or hydroxyl 
groups and, in many cases, require the presence of a base for catalyzing its 
deprotonation(82). The understanding of the metabolism of a radiotracer is also essential 
for a successful synthesis since there are frequently several positions in the molecule 
that can be labelled with the radioisotope. Ideally, active metabolites containing the 
radioisotope should not be formed, as they can mask the signal of the main radiotracer. 
PET radiotracers for the study of brain biochemistry are usually radiolabelled in a 
metabolically unstable position (e.g., a N-[11C]CH3 group) that, after administration, 
gives hydrophilic intermediate products, unable to cross BBB, which causes the brain 
signal externally detected to be exclusively related to the intact radiotracer(78). 
Some radiotracers have low radiochemical yields when labelled with [11C]CH3I. In 
these cases the methylation agent [11C]CH3OTf, a more reactive and less volatile 
species, has some advantages such as the fact that the reaction can occur at room 
temperature with smaller amounts of precursor and shorter reaction times, which 
results in higher radiolabelling yields(85, 86). The synthesis of [11C]CH3OTf is performed 
by passing [11C]CH3I in a nitrogen flow through a column filled with graphite and silver 
triflate preheated to 170° - 200° C(87). 
Methylation by the captive solvent method has been the most used technique in the 
preparation of 11C radiotracers due to the ease of automating of this procedure(88). 
Here, the methylation agent [11C]CH3I or [
11C]CH3OTf is trapped into a solid support, 
such as an HPLC loop or a solid phase extraction column (SPE), containing a solution 
with micromolar amounts of the chemical precursor dissolved in a polar aprotic solvent, 
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usually dimethyl sulfoxide (DMSO), dimethylformamide (DMF), acetonitrile (CH3CN), 
methyl ethyl ketone (MEK) or another ketone(80). This kind of solvents does not form 
hydrogen bonds with the nucleophiles, so will not suffer a loss of reactivity, and will 
have the ability to trap the methylation agent stabilizing the leaving group. 
Reactions that occur directly in a loop system associated to an HPLC and previously 
coated with chemical precursor solution allow a simplified experimental setup, easily 
automated and without significant loss of activity during the transfer to the 
chromatographic system (see Figure 2.6). Other advantages result from the fact that 
loop geometry allows the reduction of the volume of solvent used, increasing the 
concentration of the chemical precursor, which leads to faster reactions at room 
temperature and better yields(89). 
 
 
 Figure 2.6. Scheme of loop injector as a solid phase reaction system. 
 
In the last decade several 11C-labelled radiotracers have been synthesized using 
different methylation approaches. The indirect method using [11C]dimethylamine, and 
starting from brominated precursors, is an interesting alternative in the alkylation of 
compounds with dimethylamine functional groups in their structure(90). Also 
palladium-mediated methylations with [11C]CH3I either by Stille (which starts with 
tin-activated precursors) or Suzuki (which starts with organoboron precursors) coupling 
reactions have demonstrated particular interest especially because of the inherent 
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advantage  to  facilitate  the  chromatographic  separation  of  the  labelled  final 
product(80, 91). 
Similar to the optimization of reaction conditions, the development of a 
chromatographic method that enables an efficient separation of the radiotracer from the 
precursor and other secondary products is an important problem to solve in the 
radiosynthesis with 11C. However, the major challenge lies in the strict need to exclude 
from the system possible sources of contamination with humidity and atmospheric 
stable carbon that are the main causes to the critical reduction of the SA of the 
radiotracer. 
Specific activity is defined as the fraction of the radiotracer, expressed in units of 
Becquerel or Curie (Bq or Ci), in relation to the total number, both radioactive and 
stable, of molecules of that same species. This property is particularly relevant in PET 
radiotracers specifically directed to molecular targets easily saturable (e.g., receptors or 
antigens) and whose density is sometimes limited by the anatomical structures in 
study. Although Aβ plaque is not a brain receptor, the mechanism of its imaging is the 
same as that of other receptor agents. For this reason, and particularly in brain 
imaging, the coexistence of the tracer both labelled with 11C and stable 12C may lead to 
pharmacodynamic or toxic undesirable effects, as well as distorted results of the 
processes in study, due to the competitive blocking of the molecular targets with the 
cold compound. 
Synthesis of 11C radiotracers is nowadays performed in automated synthesis 
modules. This brings obvious advantages regarding radiation protection, reproducibility 
and efficiency in the radiosynthesis. Nevertheless, the procedure is far from being 
routine and for each production centre and for each radiotracer a process optimization 
procedure must be developed in order to obtain a final product that meets all 
pharmaceutical requirements for human use. 
 
2.3.2 Pittsburgh Compound B radiosynthesis 
In the late 1990s thioflavin T, a benzothiazole (BTA) that has a characteristic red 
fluorescence emission when it binds to β-sheet structures, proved to be useful in the 
histological analysis and quantification of amyloid aggregates(92). However, the 
evidence that the cationic nature of this compound hinders its passage through BBB 
has led Mathis and Klunk research group, in the year 2000 at the University of 
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Pittsburgh, to the synthesis of a neutral and lipophilic analogue 
[N-methyl-11C]2-(4'-(methylaminophenyl)-6-methylbenzothiazole ([11C]6-Me-BTA-1) that 
showed  better pharmacokinetic  and a higher affinity  for the Aβ deposits(93) 
(see Figure 2.7). The persistence on improving the characteristics of this molecule 
culminated in the synthesis of the promising so-called Pittsburgh Compound A 
([N-methyl-11C]2-(4'-(methylaminophenyl)-benzothiazole or [11C]BTA-1) with improved 
cerebral uptake(94) and then the currently known as Pittsburgh Compound B 
([N-methyl-11C]2-(4’-(methylaminophenyl)-6-hidroxibenzothiazole, [11C]6-OH-BTA-1 or 
[11C]PiB)(95). Although the early studies have focused mainly in [11C]BTA-1, subsequent 
in vitro and in vivo results have shown that although [11C]PiB does not present an initial 
high brain uptake it has, however, a lower non-specific binding, a greater regional 
homogeneity and a faster clearance from the non-pathological brain which improves 
the cerebral uptake ratio between individuals with and without AD(96). Currently there is 
a consensus that [11C]PiB is the leading PET radiotracer for the early diagnosis of Aβ 
deposits which makes it a very valuable tool for centres that meet the peculiar and 
necessary conditions for its synthesis and use(51). 
 
 
 
 
 
 
 
Figure 2.7. Structure of thioflavin T analogues and radiolabelling reactions. 
 
The main chemical precursor for the synthesis of [11C]PiB is 
2-(4'(aminophenyl)-6-hidroxibenzothiazole (6-OH-BTA-0) synthesized from the 
processing of 4-methoxy-phenylamine into the corresponding nitrothiobenzamide with 
  
  
  
 
22 
 
subsequent cyclization, reduction of nitro functional group and demethylation(96). First 
attempts to the direct methylation of this precursor with [11C]CH3I showed a higher 
reactivity of the hydroxyl group and that the desirable [11C]N-methylation was not 
detectable, which originated a radiotracer with uninteresting pharmacokinetics 
(6-[11C]MeO-BTA-0). Protection of the phenol with a methoxymethyl group 
(6-MOMO-BTA-0) has favoured the nucleophilic substitution in the primary amine but 
requires an additional deprotection step which increases the reaction time, the need of 
more aggressive conditions and the use of more refined purification techniques to 
obtain  [11C]PiB  in  a  final  saline  solution  suitable  for  i.v.  administration(96)  
(see Figure 2.7). 
Using [11C]CH3OTf as a direct methylation agent of the desmethyl precursor 
6-OH-BTA-0 by a loop captive solvent method, Wilson and his co-workers have 
developed a more efficient radiolabelling methodology of [11C]PiB which only causes 
secondarily a vestigial amount of [11C]MeO-BTA-0 easily separated from the final 
solution by HPLC(97) (see Figure 2.7). Considering that [11C]CH3OTf is more reactive 
and less volatile than [11C]CH3I, its methylations can occur without the use of forced 
conditions - which often promote the formation of side products that must be removed - 
and can be easily trapped and confined into limited geometries, such as a loop 
system(87). 
With the commercial availability of the precursor 6-OH-BTA-0, this last method has 
become the main route for the preparation of [11C]PiB and, since then, several 
authors(97-102) have automated and optimized it for their particular laboratory realities, 
which means that there is no consensus on what are the more suitable reaction 
conditions (temperature, time of reaction, solvent and precursor concentration) since 
these ultimately depends on the particularities of each synthesis system assembled. 
That is why it is essential to optimize the whole process of [11C]PiB synthesis when it is 
originally implemented in a research or diagnostic centre. 
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3. Justification of the project 
 
This scientific and technical work that support this thesis were performed at ICNAS 
with the aim of establishing an automated and reproducible process for radiolabelling of 
[11C]PiB, through the captive solvent method, and further purification and reformulation 
in a sterile and pyrogen-free injectable solution. The goal was to produce a sterile 
apyrogenic injectable solution of [11C]PiB with good yields, high purity and adequate SA 
for human studies. 
Since the academic degree involved has a main objective of providing vocational 
qualifications and skills that aim to contribute to an improvement of healthcare, we 
consider that this project totally fulfils that purpose. 
The fact that the synthesis of [11C]PiB is described in the literature does not affect the 
importance of this project as its radiolabelling, purification, and reformulation in a sterile 
non-pyrogenic injectable are new in Portugal and need to be adapted for local 
applicable regulations. Moreover, this process is not fully described when using the 
sequential line of the automated modules MeI-PlusTM, AutoLoopTM and 
ReFORM-PlusTM (Bioscan Inc. Washington DC, USA) and several parameters need to 
be optimized for a successful, reliable and reproducible synthesis. Conversely, the 
existence of vast scientific evidences that confirm the technical importance of 
[11C]PiB-PET/CT in early clinical diagnosis of AD reinforces the need of its availability 
to the population in face of a health problem with such great impact on contemporary 
societies. 
In a radiopharmacy expertise degree that aims primarily to provide Nuclear Medicine 
students with important qualifications for their professional life (taking into account the 
available resources and the labour market demands due to the technological and 
scientific evolution) we consider very pertinent to chose the optimization of an already 
known radiotracer with real impact on the clinical practice rather than investing all 
efforts in new chemical entities developed with investigational purposes that, many 
times, have more in mind to advance the radiochemistry science than to respond to 
real needs of the clinical practice. These results, despite giving origin to dissertations of 
undeniable interest, typically are too centred on the theories and techniques which 
deflect them from what should be their true assumption: to assist with actually relevant 
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radiopharmaceuticals, that meet the needs of clinical molecular imaging, in order to 
have a real impact on populations and healthcare systems. 
Considering that the proposed project involved highly specific equipment, complex 
chemical reagents and short-lived radionuclides, it was essential to use a radionuclide 
production facility containing a cyclotron and a radiochemistry laboratory with the 
automated synthesis modules and all other devices and materials needed for the 
realization of such a work. Bearing in mind the costs involved, the project was 
subjected to scientific and economical evaluation by ICNAS and it was considered very 
relevant taking into account the objectives of the centre, as laid down by its scientific 
council, and also economically viable considering the potential for human studies. The 
interest of ICNAS in the results was crucial for the development of the work and 
corroborates the relevance and appropriateness of this project. 
The work was conducted under Good Laboratory Practices (GLP), Good 
Manufacturing Practices (GMP) and current Good Radiopharmacy Practices. (cGRPP). 
Research with this compound was submitted to the University of Coimbra ethics 
committee for human use and approved for clinical studies. This entity falls within the 
responsibility of the Portuguese Decreto-Lei nº 97/95 of May 10th and Lei nº 46/2004 of 
August 19th, according to Artigo 12º from Regulamento Interno do ICNAS, to certify the 
execution of ethical standards in the exercise of medical sciences, in order to protect 
and ensure human dignity and integrity, by conducting an analysis and reflection on 
issues of clinical practices that may involve an ethical discussion. 
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4. Methodology 
 
The preparation of the radiotracer was based on the captive solvent method 
developed by Wilson and co-workers(97). The processes of radiolabelling, purification 
and reformulation of [11C]PiB were automated in order to obtain a sterile, 
non-pyrogenic, injectable solution to carry out PET research studies. Starting from 
[11C]CO2 produced in a Cyclone
® 18/9 cyclotron (IBA©, Louvain-La-Neuve, Belgium) by 
the 14N(p,α)11C nuclear reaction in a N2 + 0.5% O2 gaseous target, the synthesis of the 
radioactive precursor [11C]CH3I and then [
11C]CH3OTf by the “wet method” was 
optimized, using the MeI-PlusTM module. By reacting, at room temperature, in the 
AutoLoopTM system, the produced [11C]CH3OTf and the commercially available 
demethylated precursor 6-OH-BTA-0 under various conditions (time, solvent, 
concentration) the most favourable results for the [11C]PiB production were determined 
and its quality, after reformulation in the ReFORM-PlusTM module, was confirmed 
through previously optimized analytical methods (see Figure 4.1). 
The radiosynthesis was carried out in a hot cell with the operator making exclusive 
use of remotely controlled equipment, manipulators and valves whilst visually 
monitoring all the process through a leaded-glass window and by a software program 
that gives a graphical view of each operation and monitored function (flow, pressure, 
temperature and radioactivity). In-process controls provided the evidence of the 
intermediate and final results and were collected and recorded throughout the course of 
the procedure. 
 
 
Figure 4.1. Scheme of the adopted [
11
C]PiB synthesis process. 
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4.1 Instruments and materials 
Apart from the Bioscan Inc. commercial modules previously described and IBA© 
cyclotron Cyclone® 18/9, several other specific and scientific devices were needed for 
this project (see Figure 4.2). 
All radiochemistry procedures were carried out in a shielded MIP1-1P hot cell 
(Comecer SPA©, Castel Bolognese, Italy). The semi-preparative HPLC system, coupled 
in series with AutoLoopTM, was composed by a Wellchrom HPLC-Pump K-501 and a 
K-200 WellChrom fixed ultraviolet (UV) wavelength (254 nm) detector (Knauer GmbH©, 
Berlin, Germany) equipped with a Luna C18(2), 5 µm, 10x250 mm (Phenomenex®, 
Torrance, USA). 
 
 
Figure 4.2. Diagram of the interactions between the devices involved. 
 
Analytical equipment for quality control consisted of an Agilent 1200 Series HPLC UV 
system equipped with a Zorbax Eclipse XDB-C18 column, 5 µm, 4.6x150 mm (Agilent 
Technologies©, California, USA) and a GABIstar NaI(Tl) radiometric detector controlled 
via GINAstar software (Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany). 
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A Jenway 3510 pH meter (Bibby Scientific Limited©, Staffordshire, UK), an ISOMED 
1010 dose calibrator (Nuklear-Medizintechnik Dresden GmbH, Dresden, Germany) and 
an Agilent 6850 Series II gas chromatography (GC) system with a HP-Fast GC Residual 
Solvent (6% Cyanopropylphenyl and 94% dimethylpolysiloxane, phase composition) 
capillary column (Agilent Technologies©) associated to a (FID), were also used. 
The precursor 6-OH-BTA-0 (chemical purity >95%) and the cold PiB reference 
standard (6-OH-BTA-1) were obtained from ABX (ABX-Advanced Biochemical 
Compounds, Radeberg, Germany) while “cold” CH3I was purchased from VWR
® (VWR 
International SAS, Fontenay-sous-Bois, France). The reagents LiAlH4 (0.1 M solution in 
dried THF) and HI (aqueous solution 57% redistilled over red phosphorus) were also 
obtained from ABX. Silver triflate, with trace metals basis upper than 99.95%, 
(Sigma-Aldrich®, Steinheim, Germany) and graphite powder (Bioscan Inc.) were used to 
prepare the column that converts [11C]CH3I to [
11C]CH3OTf. Molecular sieve adsorbent 
(13X, 100/120mesh), sodium hydroxide pellets (NaOH), phosphorus pentoxide (P2O5), 
CO2 absorbent Ascarite II
® (20-30 mesh) and ammonium formate (NH4HCO2) were 
purchased from Sigma-Aldrich®. Vented and 0.22 µm sterilization filter units (Millipore®, 
Carrigtwohill, Ireland) as well as three different kinds of C18 SPE cartridges (Waters®, 
Milford, USA) were used in the reformulation process. 
All solvents were obtained from commercials suppliers at European Pharmacopoeia 
(Ph. Eur.), HPLC or pro analysis grade, as appropriate, and used without further 
purification while sterile water for injections (WFI) and 0.9% sodium chloride (NaCl 
0.9%) were obtained from B. Braun© (B. Braun Melsungen AG, Melsungen, Germany). 
Pharmaceutical gases were purchased from Praxair© (Praxair Technology Inc., 
Danbury, USA) according to the composition and purity described in the Ph. Eur. 
 
4.2 Experimental procedures 
All of the procedures involving handling of radioactive substances were carried out in 
a radiochemistry laboratory with the standard required conditions of radiological 
protection and safety. The use of personal protective equipment and lead or tungsten 
barriers, with appropriate thickness to the manipulated activities, was equally 
transversal to all experimental procedures. 
The adherence to GLP/GMP regulations, which deal with the organization, processes 
and conditions under which investigational studies should be planned, executed, 
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monitored and reported, became also essential to ensure that all data have been 
collected appropriately and that the inferred conclusions are valid. So, the date of 
receipt, quantity received, manufacturer, lot number, certificates and expiration date 
were recorded and archived for each of the components, materials reagents and 
supplies received and used. 
 
4.2.1 Optimization of the chromatographic conditions 
To optimize the chromatographic conditions for separation of PiB from the precursor 
6-OH-BTA-0 and CH3I it was carried out a bibliographic search of the HPLC eluent 
system and it was chosen the most appropriate flow for the used analytical (Zorbax 
Eclipse XDB-C18, 5 µm, 4.6x150 mm) and semi-preparative (Luna C18(2), 5 µm, 
10x250 mm) columns. 
The majority of the literature consulted mentions, as mobile phase of a reversed 
phase chromatographic system, an isocratic aqueous solution of 60% CH3CN and 
40% H2O
(97, 103-105) that, due to the presence of ionizable functional groups on the 
analyte, requires the addition of a buffer to adjust pH between 6.5 and 7.0. A 0.1 N 
ammonium formate buffer was used. 
After selection of the chromatographic conditions that allowed a better performance in 
the separation of the analyzed compounds, these were identified by HPLC using 
commercially available reference standards and a calibration curve for subsequent 
quantification of PiB was built. 
 
4.2.2 Production of [11C]CH3I and [
11C]CH3OTf 
All PTFE and PEEK tubing as well as 3-way solenoid and 2-way pinched valves of 
MeI-PlusTM system were previously washed with ethanol, acetone and diethyl ether 
provided from solvent delivery module (see Figure 4.3). The LiAlH4/THF and Hi reagent 
vials were also replaced by HCl 0.1 M and ethanol vials, respectively, to ensure the 
cleanliness of the dispensing valves, tubing and reactor. Finally all the system was 
carefully dried under a continuous nitrogen flow during at least 10 minutes, the 
LiAlH4/THF and Hi reagent vials were then correctly placed in their corresponding 
positions and the module was pressurized to avoid external contamination. 
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Carbon-11 was initially produced in the form of [11C]CO2 at the cyclotron via the 
14N(p,α)11C in an aluminium body target loaded with N2/0.5% O2 gaseous mixture 
(purity above 99.99%) and covered with an aluminium window foil. The gas was 
irradiated with protons (effective beam energy on target of 16 MeV) with an integrated 
current between 10 to 14 µAh and the irradiation was stopped as soon as the desired 
activity level was reached. After cyclotron bombardment the [11C]CO2 was transferred 
by spontaneous expansion, through a stainless steel tube, to the synthesis module 
placed inside a hot cell in the radiochemistry laboratory. The radioactivity and its path 
along all the synthesis process can be monitored through several detectors 
strategically placed in the modules and hot-cell. 
In a first step [11C]CO2 is trapped at room temperature in a copper column filled with 
molecular sieves (see Figure 4.4A). This column is previously conditioned by heating it 
at 250º C for at least 20 minutes and then cooled to remove traces of stable CO2 which 
ensures a better SA. The reactor vessel is also prefilled with a given volume of 
LiAlH4/THF. After the trapping of the [
11C]CO2, the molecular sieve column oven is 
heated at 250º C under 12 ml/min continuous nitrogen flow during at least 1.5 minutes. 
This releases the [11C]CO2 from the column forcing it to bubble in the LiAlH4/THF 
solution where is trapped in the reactor. Once the [11C]CO2 is completely trapped, THF 
is evaporated to dryness (>2 minutes at 115º-120º C) and an excess of HI (350-450 µl) 
is added to generate [11C]CH3I which was then distilled under continuous nitrogen flow 
(3 minutes at 115º-120º C). 
The volume of LiAlH4/THF dispensed from the sealed vial was optimized to achieve a 
minimum amount capable of producing satisfactory conversion yields of [11C]CH3I. This 
is critical to SA, since atmospheric CO2 is also trapped in the LiAlH4/THF solution and 
the non-radioactive species derived from it are generated before the treatment with HI. 
While other 11C species go into waste, the distilled [11C]CH3I passes with a nitrogen 
flow rate of around 12 ml/min through a 180º C preheated column filled with a not too 
much compressed mixture of graphite and silver triflate (see Figure 4.4B) to form 
[11C]CH3OTf. Since it is essential to ensure the homogeneity of this mixture it was 
produced by adding in a reaction flask 1 g of silver triflate, 2 g of graphite and 30 ml of 
diethyl ether under stirring for about 10 minutes. After evaporation of diethyl ether the 
column was prepared as fast as possible and placed protected from light into the 
system. 
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The introduction of a NaOH or P2O5/ascarite drying column (see Figure 4.4C-D) 
before [11C]CH3OTf production was tested to reduce traces of humidity in the tubing 
which can lead to greater amounts of [11C]CH3OH in the final product. 
 
 
 Figure 4.4. Columns used on the synthesis of [
11
C]CH3OTf. 
 
4.2.3 Production of [11C]PiB in a captive solvent loop 
After being synthesized, the [11C]CH3OTf coming from the earlier automated 
methylation system was delivered by a nitrogen gas stream to a stainless steel reaction 
loop (1/16-inch outer diameter tubing, 2 ml of internal volume) maintained at room 
temperature and previously coated with the chemical precursor solution. The 
6-OH-BTA-0 precursor was prepared in several solvents (MEK, DMF, DMSO, CH3CN 
and acetone) and under different conditions (0.5 mg/80 µl, 1 mg/80 µl, 1 mg/100 µl and 
1 mg/160 µl) to determine which yielded better results. After dissolving the precursor by 
stirring in a vortex the solution was promptly and slowly injected (5-10 s) into the clean 
dry AutoLoopTM injector valve using an 100 µl HamiltonTM syringe (Hamilton Company, 
Bonaduz, Switzerland). 
Radioactivity trapped on the loop was detected by a proximal radiometric detector 
(see Figure 4.3) and after complete capture of the activity the loop was sealed and the 
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nitrogen flow stopped which allows the reaction to occur. In this work it was tested 1, 2, 
3 and 4 minutes reaction time at room temperature. 
The products of the reaction were then transferred, by passing a mobile phase of 
CH3CN/H2O (40/60) with 0.1 N NH4HCO2 through the loop with a flow rate of 9 ml/min, 
to a semi-preparative HPLC system to carry out the purification of the desired fraction. 
 
4.2.4 Purification and reformulation of the final product 
The crude product resulting from the reaction of 6-OH-BTA-0 with [11C]CH3OTf was 
carried by the mobile phase (CH3CN/H2O (40/60) + 0.1 N NH4HCO2, flow rate of 
9 ml/min) through a HPLC semi-preparative Phenomenex® Luna C18(2) 5µ column 
(250x10 mm) installed in series with an UV detector set at 254 nm and a reformulation 
system (ReFORM-PlusTM) with a radiometric detector for separation of the different 
chemical and radiochemical species. 
After its retention time (rt) has been identified previously by the HPLC injection of a 
cold standard, the desired [11C]PiB peak was collected for reformulation into a 
physiological and sterile solution suitable for i.v. administration. 
The reformulation process was established in a disposable 5-way stopcock manifold 
system installed at ReFORM-PlusTM (see Figure 4.3) and the flow of the solutions 
involved impelled by remotely controlled pressurization and/or vacuum of the desired 
compartments. After its separation and collection, the fraction containing [11C]PiB was 
firstly diluted with 10-15 ml of WFI where it bubbled for a few seconds to ensure 
efficient mixing and then it was trapped in a SPE cartridge monitored by a radiometric 
detector. Three types of silica-based bonded phase SPE cartridges (C18 Plus Light, 
C18 Plus Short and tC18 Plus Long Sep-Pak from Waters®), previously hydrated and 
activated with ethanol, were tested for their ability to retain [11C]PiB using the minimum 
amount of ethanol. 
The SPE cartridge was then washed in 10-15 ml of WFI to remove the organic 
solvents from the mobile phase leaving only [11C]PiB trapped due to its hydrophobicity 
which makes it hardly soluble in water. The loaded cartridge was successively eluted 
with 0.4-1.0 ml (according to the type of cartridge tested) of ethanol and 9 ml of NaCl 
0.9% and sterilized by 0.22 µm filtration before reaching the sterile final vial. The 
amount of radioactivity of the final radiotracer was measured in a dose calibrator and a 
sample was subject to quality control. 
  
  
  
 
33 
 
In the end of each production cycle, a cleaning procedure was run to remove all 
residual radioactivity and chemicals in the modules. This cleaning procedure consists 
of passing ethanol, acetone and ether to wash the methyl iodide production system and 
water followed by ether and acetone in the reactor loop. A final drying step with 
nitrogen was performed in both modules and, after a new preconditioning of the 
molecular sieve column, the system was prepared for next synthesis. 
 
4.2.5 Quality control 
After measurement in a dose calibrator to calculate the radioactive yield, the final 
formulation of [11C]PiB was subjected to a visual inspection. The solution examined 
should be clear and colourless with no visual evidence of cloudiness or particulate 
matter. Then, and according with the radiopharmaceutical preparations monograph of 
Ph. Eur., the pH of the solution was measured with a potentiometer to see if it has the 
value between 4.5 and 8.5 suitable for i.v. administration. 
Chemical and radiochemical purity and identity were analyzed through a HPLC 
equipped with an UV and radiometric detector and a Zorbax Eclipse XDB-C18 column, 
5 µm, 4.6x150 mm (Agilent Technologies©) using CH3CN/H2O (40/60) + 0.1 N 
NH4HCO2 as mobile phase with a flow rate of 4 ml/min. After verifying the stability of 
the analytical HPLC system the radiochemical identity of [11C]PiB is confirmed if its rt 
corresponds, with a small deviation resulting from the distance between the UV and 
radiometric detectors, to that of cold PiB standard solution previously injected. 
To ensure the radiochemical purity, the area of the radioactive peak corresponding to 
[11C]PiB shall represent more than 95% of the sum of all radioactive peaks areas 
existing in the chromatogram since potential radiochemical impurities, such as 
[11C]CH3OH, [
11C]CH3I and [
11C]CH3OTf, were removed during the semi-preparative 
HPLC purification. 
Although radiochemical purity for radiotracers typically must be >95% there are 
currently no chemical purity requirements for their release in clinical research. Since 
potential non radioactive impurities in the final solution, such as the precursor 
6-OH-BTA-0 and traces of LiAlH4 not carried over during the distillation procedure or 
HI, were also eliminated by semi-preparative HPLC and C18 Sep-Pak the chemical 
purity should remain as high as the radiochemical. Therefore SA must be the main 
property to be evaluated. 
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Specific activity is the fraction of the radiotracer in relation to the total number of both 
radioactive and stable molecules of that same species (GBq/µmol) and is particularly 
relevant in PET radiotracers specifically directed to micromolar quantities of molecular 
targets. To quantify this property the area under [11C]PiB UV mass peak was fitted to a 
standard calibration curve previously generated through several concentrations of cold 
PiB injected in the same HPLC system and related with the sample radioactivity. 
Levels of organic volatile impurities were analyzed through the injection of 2 µl of the 
final solution into a gas chromatographer equipped with a FID and previously calibrated 
for the residual solvents in analysis. Since [11C]PiB injection vehicle is 5% ethanol and 
95% saline it is expected a prominent peak of ethanol in the chromatogram. By being 
part of the mobile phase the main residual solvent to be controlled is acetonitrile and its 
concentration in the final solution shall be, according to Ph. Eur., less than 4.1 mg/V 
where V is the maximum injected volume in ml. 
Radionuclidic identity of the involved radioisotope was confirmed by measuring its t1/2 
across several assays in a dose calibrator. The final result was compared with the 
characteristic t1/2 of 
11C (20.4 minutes) with a margin of ±5%. 
The integrity of the 0.22 µm sterile filter was determined after use in the production of 
[11C]PiB by the bubble point test (BPT). The sterile filter attached with the inlet needle 
to the final vial is also connected to a nitrogen supply regulator. After removing the final 
vial with the radiotracer the needle attached to the sterile filter is submerged in water 
and the nitrogen pressure gradually increased. It was considered that the filter 
guaranteed the sterility of the [11C]PiB solution if the pressure was raised between the 
maximum value achieved during the reformulation process (typically 2 bar) and the limit 
supported and specified by the filter without seeing a stream of bubbles. 
Finally, after i.v. administration of [11C]PiB, the bacterial endotoxins content in the 
radiotracer was analysed using the limulus amebocyte lysate (LAL) test. This involves 
incubation (37º C) of the limulus lysate reagent (Charles River Laboratories EndoSafe®) 
with a sample of our solution for 60 minutes to determine if there was a potential 
contamination above 17.5 endotoxins units per ml. 
The synthesized [11C]PiB solutions were stored at room temperature in the original 
sterile vial sealed with a butyl rubber stopper and aluminium capsule for possible 
subsequent tests. 
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5. Results and discussion 
 
The developed process aimed to obtain, in good yields, a final sterile and saline 
[11C]PiB solution with a SA suitable to be used in human studies. Although the 
productions of [11C]CH3I by the “gas phase method” present higher specific activities 
they have the disadvantage of providing lower radiochemical yields. So, considering 
the characteristics of the “wet method” automated methylation system used, the main 
goal was to improve SA by reducing the global time of the synthesis and increasing the 
radiochemical yield which, consequently, may raise the final specific activity. 
All experiments were performed at least 3 times (n=3), to achieve a minimally 
acceptable level of confidence, and mostly carried out through long irradiation periods 
(integrated current of approximately 12 µAh during 30 minutes) to create the same 
conditions for a production destined to clinical use. Shorter productions could facilitate 
the collection of data but, when extrapolated to the bigger ones required to reach the 
necessary activity for human studies, might introduce a possible error associated with 
the particular conditions submitted in the cyclotron target. Actually is widely accepted 
that, for example, by varying the beam current and the irradiation time, different 
sources of carrier carbon have to be considered(105, 106). 
 
5.1 Chromatographic system 
Due to its short t1/2, the synthesis of 
11C labelled radiotracers must be performed as 
quickly as possible. Commonly this process is particularly optimized during the 
chemical reaction steps but efforts should be made also to refine the chromatographic 
system since a long separation time, either during the purification or the checking of the 
quality parameters prior to administration, will obviously limit the total radioactivity of 
the radiotracer available. 
From the selected mobile phase CH3CN/H2O (40/60) with 0.1 N NH4HCO2, and 
knowing that generally the introduction of a methyl group in a molecule increases its 
lipophilicity, we used reversed phase C18 HPLC columns both in the analytical (Zorbax 
Eclipse XDB-C18, 5 µm, 4.6x150 mm) and semi-preparative (Luna C18(2), 5 µm, 
10x250 mm) systems. The separation mechanism through reversed phase 
chromatography depends on the hydrophobic binding interaction between the solute 
molecule in the mobile phase and the stationary phase. In our case this last one is 
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composed by an octadecyl carbon chain (C18) bonded in silica. This highly efficient 
stationary phase for hydrophobic compounds which, for having lower polarity than that 
used in normal phase chromatography allows the use of less toxic mobile phases 
composed by common organic solvents of high polarity, is particularly suitable for an 
appropriate separation of molecules intended for i.v. administration. 
Because in radiochemical synthesis the precursor is always used in large excess, a 
considerable amount of this product is expected at the final crude mixture. To prevent a 
predictable and severe tailing effect of this major peak in the chromatogram, able to 
mask and contaminate the peak of the compound of interest that is intended to 
separate and collect, we need to ensure a sufficient difference between each retention 
time (rt) so that there is no overlap of the two species since this would irreversibly affect 
the purity of the final product. 
After the individual identification by analytical HPLC of the cold reference standards of 
6-OH-BTA-0, CH3I and PiB in different flow rates it was concluded that the one that had 
shorter rt, in order to prolong the chromatographic run as least as possible, and enough 
resolution to be capable to separate the various compounds making them easily 
distinguished and identified, was 4 ml/min (6-OH-BTA-0 rt=0.94±0.04 min, CH3I 
rt=1.43±0.06 min, PiB rt=1.82±0.09 min). To confirm the selection of these parameters 
we also injected a mixture of different concentrations of each reference standard to 
better  understand  the  separation  achieved  between  the  three  solute  molecules  
(see  Figure 5.1). 
The same procedure was repeated for the semi-preparative system where we used 
the highest flow rate possible, taking into account the maximum pressure supported by 
the installed HPLC column (22 bar). With a flow rate of 9 ml/min we obtained rt of 
3.71±0.11 min, 5.83±0.18 min and 6.88±0.44 min for 6-OH-BTA-0, CH3I and PiB, 
respectively (see Figure 5.2). 
An adequate HPLC resolution, generally defined as the distance between the centres 
of two eluted peaks divided by the average width of the respective peaks, is particularly 
essential at semi-preparative systems since it is important to ensure that by collecting 
100% of the interesting peak we will get it theoretically with 100% of purity. This has 
major interest in the need to ensure that the collected peak corresponding to [11C]PiB is 
free of impurities which would reduce the final chemical and radiochemical purity of the 
final solution. Of these impurities, we must take into account particularly the ones 
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related to the precursor 6-OH-BTA-0 that, due to their biological activity, can compete 
in vivo for the same target. 
 
 
 Figure 5.1. Analytical HPLC of cold standards mixture. 
 
The calculated resolution achieved between PiB and its precursor with the chosen 
chromatographic system was approximately 4, which ensures total purity of the 
collected specie over the other. The distance to the CH3I peak is not as critical since 
this one is efficiently eliminated from the final radiotracer solution by subsequent SPE. 
 
 
Figure 5.2. Semi-preparative HPLC of cold standards mixture. 
 
Summarizing, the chromatographic conditions used during all purification and quality 
control process were, an isocratic CH3CN/H2O (40/60) + 0.1 N NH4HCO2 mobile phase, 
a flow rate of 9 ml/min with a Luna C18(2) HPLC column (5 µm, 10x250 mm), for the 
  
  
  
 
38 
 
semi-preparative, and a flow rate of 4 ml/min with a Zorbax Eclipse XDB-C18 HPLC 
column (5 µm, 4.6x150 mm), for the analytical system. 
By injecting in the analytical HPLC system 4 replicates of 3 different known 
concentrations of the cold PiB standard we constructed a reference curve in order to 
subsequently infer, through the UV peak area corresponding to PiB fraction, the 
concentration of the final radiotracer solution (see Figure 5.3). From this value and from 
the known total activity and final volume we are able to calculate SA of [11C]PiB after 
synthesis and before injection time. 
 
 
Figure 5.3. Reference curve for the calculation of PiB concentration. 
 
5.2 Synthesis of [11C]CH3I and conversion into [
11C]CH3OTf 
Since 1976, when it was first prepared to synthesize [11C]methionine, [11C]CH3I is the 
most common secondary radioactive precursor used for 11C radiolabelling(107). The 
used commercial automated methylation system allow its preparation by the very 
reliable “wet method” where [11C]CO2 is firstly reduced to [
11C]CH3OH, by action of 
LiAlH4, and then reacts with HI in order to generate [
11C]CH3I (see Figure 5.4). 
Although being a very efficient method that leads to appreciable absolute quantities of 
[11C]CH3I, this technique however suffers from the drawback of relying on the 
relationship between the produced [11C]CO2 and the atmospheric CO2 existing in the 
reaction environment, which normally results in low specific activities. 
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[11C]CO2 [
11C]CH3OH
HI
[11C]CH3I
115ºC-120ºC
LiAlH4
 
Figure 5.4. Synthesis of [
11
C]CH3I by the “wet method”. 
 
Knowing that the contamination of the cyclotron target and gas lines with [12C]CO2 is 
practically unavoidable, leading to a theoretical contamination of 100-1000 atoms of 
stable carbon for each 11C atom produced(33), is important to reduce all other 
contamination factors that can be more easily controllable. Procedures to reduce the 
amount of “cold” CO2 that enters in the system, like the introduction of an ascarite trap 
between the N2 supply and the MeI-Plus
TM module or a routine search for leaks, can 
bring significant results. However several authors have been pointing LiAlH4/THF 
solution as the main source of this contaminant(106, 108, 109). 
In fact the use of LiAlH4/THF can be the critical point to obtain higher specific activities 
since the formation of non-radioactive species may occur prior to its introduction in the 
automated system by reduction with environmental CO2 during handling or improper 
storage. Once in situ preparation of LiAlH4 dissolved in dry THF requires strict 
conditions of inert atmosphere, the adopted option during the development of this 
project was to use 0.1 M commercially available sealed solutions (with a background of 
less than 5 ppm of [12C]CO2) released in lower volumes so that can be discarded after 
each perforation of the vial rubber stopper when used in the automatic [11C]CH3I 
production module. 
The central oxygen of THF eventually remaining after evaporation can also react with 
LiAlH4 hydride ions originating carrier carbon under the form of methanol. Ways to 
counteract this chemical effect include doing an efficient THF evaporation (3 to 4 
minutes at 115º-120º C proved, through visual check, to be sufficient for the absence of 
droplets residues in the reactor while lower temperatures, for example 105º C, revealed 
some presence of aqueous substances), maximizing the concentration of the 
LiAlH4/THF solution (in the presented study we used a 0.1 M solution but there is also 
commercially available an 1.0 M formulation, so the results using this higher 
concentration could be evaluated in the future) or reducing the release in the reactor 
vessel of this reagents to the minimum amount possible without affecting [11C]CO2 
trapping or [11C]CH3I production after treatment with an excess (350-450 µl) of HI. 
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To optimize this last parameter a set of experiments were carried out in order to reach 
the minimum volume of LiAlH4 in dry THF (0.1 M) that must be used to an effective 
trapping of [11C]CO2 and further production of [
11C]CH3I (see Table 5.1). 
 
Table 5.1. LiAlH4 volume influence in [
11
C]CO2 trap and 
[
11
C]CH3I production. 
LiAlH4/THF (0.1 M) 
volume 
Yield of [
11
C]CO2 
trapping* 
Yield of [
11
C]CH3I 
production* 
250 µl (n=3) 93.8±4.1% 77.9±5.1% 
200 µl (n=5) 90.3±2.3% 72.0±9.3% 
150 µl (n=3) 88.1±2.3% 73.2±3.2% 
100 µl (n=4) 92.1±4.5% 77.5±3.5% 
75 µl (n=3) 89.9±5,8% 77.4±4.1% 
 *Decay corrected (DC) values 
 
It was observed that the volume of LiAlH4 employed does not significantly affect the 
quantity of [11C]CO2, coming from the molecular sieve column, that is trapped in the 
reactor vessel. After reaction with HI the yields of production of [11C]CH3I also remained 
practically constant (note that these values take into account possible radiochemical 
impurities, such as unreacted [11C]CH3OH, which may be present in the reactor crude 
mixture and cannot be separated) between a LiAlH4 volume of 75 to 250 µl. The 
release of radioactivity from the molecular sieve column and the follow up of its 
dynamics  in  the  reactor  vessel  were  monitored  by  radiometric  detectors  
(see Figure 5.5). 
Since it is known that the decrease of the quantity of LiAlH4/THF is a critical point that 
inversely affects final SA of a radiotracer(109) it was selected a volume between 75 to 
125 µl for the synthesis of [11C]CH3I. This range of values was chosen to take into 
account a possible error inherent to the automatic dispenser of the MeI-PlusTM system, 
because when selecting strictly 75 µl it would be a risk that the released volume was 
lower than the expected. 
After synthesis, the resulting [11C]CH3I is dried and separated from some side 
products by distillation under continuous nitrogen flow (approx. 3 minutes at 
115º-120º C). Distillation is a separation method based on the vapour-liquid equilibrium 
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phenomenon that allows that two or more substances, with different volatilities, forming 
a liquid mixture can be isolated. However [11C]CH3OH (boiling point of 65º C), the more 
relevant radiochemical impurity, remains blended in [11C]CH3I (boiling point of 43º C) 
since the distillation temperature makes both compounds gaseous. A decrease in 
temperature to a value between the two boiling points is not a viable alternative 
because it turns the distillation process of [11C]CH3I too slow, which is inconsistent with 
the indispensable quickness when working with 11C, and, furthermore, it is also 
reported that a distillation temperature lower than 110º does not lead to the formation of 
any product(99). So, as will be discussed, a subsequent separation by semi-preparative 
HPLC is a more efficient process to remove [11C]CH3OH from the final solution. 
 
  
Figure 5.5. [
11
C]CH3I production profile. (A) maximum [
11
C]CO2 
trapping after cyclotron production. (B) beginning of [
11
C]CO2 release 
by heating; (C) maximum [
11
C]CO2 trapping by reduction of LiAlH4; 
(D) THF evaporation followed by HI reaction; (E) maximum level of 
[
11
C]CH3I produced and beginning of distillation. Molecular sieve 
detector (solid line) and reactor detector (dotted line) profiles are 
shown. 
 
Once 6-OH-BTA-0 does not react at room temperature with [11C]CH3I (all experiments 
carried out at these conditions did not lead to the formation of [11C]PiB) the reactivity of 
the electrophilic carbon of this radioactive precursor was improved by preparing the 
methylation agent [11C]CH3OTf. For this, the distilled [
11C]CH3I was passed in a 
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nitrogen flow through a conversion column, filled with graphite and silver triflate and 
preheated at 180º C, to suffer a quantitative reaction (virtually 100% yield). 
Between the distillation and the conversion column two types of drying columns were 
tested since the possible presence of traces of gaseous HI can react with oxygen 
originating H2O molecules that, in contact with [
11C]CH3OTf, can lead again to the 
formation of the radiochemical impurity [11C]CH3OH. A drying column formed by P2O5 
(that removes traces of H2O) and ascarite (a trap for the excess of HI) revealed to be 
more efficient than the NaOH column commonly reported in literature. The removal of 
acid and water is necessary for a good methylation yield and the distillation via 
P2O5/ascarite trap shown to lead to lower amounts of [
11C]CH3OH. This was observed 
at semi-preparative HPLC chromatogram where [11C]CH3OH have a rt of 1.56±0.35 
minutes (see Figure 5.6). In all experiments performed the formation of this by-product 
was directly associated with residual humidity present on the lines and columns. For 
that reason before the first daily synthesis all lines, including the one passing through 
the column in triflate oven, were dried with a nitrogen flow. 
 
 
Figure 5.6. Semi-preparative HPLC of [
11
C]PiB and main 
radiochemical impurities. 
 
The preparation of the conversion column is also quite important since a poor 
homogenization of graphite and silver triflate mixture may cause an incomplete 
conversion of [11C]CH3I which, although not reacting with 6-OH-BTA-0 precursor to 
form [11C]PiB, will be an additional radiochemical impurity in the final crude mixture 
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(see Figure 5.6). An excessive compression of that mixture also proved to be 
problematic as it could lead to an inexistent or excessively slow conversion rate of 
[11C]CH3OTf due to the inability of the nitrogen flow carrying [
11C]CH3I to efficiently 
cross the column. 
This optimization of the [11C]CH3I synthesis process and subsequent conversion to 
[11C]CH3OTf is an essential step to move forward toward 6-OH-BTA-0 radiolabelling. 
 
5.3 The reaction by the captive solvent method 
Iwata et al.(108) concluded that, after ensuring the care in LiAlH4/THF handling and 
reducing its volume to the minimum possible, further optimization of the SA values are 
difficult to obtain. So, the increasing of starting 11C activity, the optimization of reaction 
conditions to get higher yields and the shortening of synthesis time will be the most 
appropriate solutions to get better results. 
Using the captive solvent method the trapping and reaction of [11C]CH3OTf with the 
chemical precursor occurs directly in the injection loop of a HPLC allowing a rapid 
release of the crude mixture in the purification system. The major advantage of this 
method lives in the loop geometry that allows to reduce drastically the solvent volume 
(compared to bubbling reaction in vessels), increasing the concentration of the 
precursor solution, leading to fast rates of reaction at room temperature and neutral 
conditions. Since no vials, transfer lines, cooling, heating, or sealing valves are 
required, no transfer losses occur, yields are high, and the contamination is minimal, 
this method is ideal for the rapid preparation of [11C]radiotracers(89). 
After [11C]CH3OTf conversion the activity leaves the column filled with graphite and 
silver triflate and reaches the reaction loop pre-filled with a solution of the chemical 
precursor. This phase is monitored by a radiometric detector installed at the centre of 
the loop and another one in a trap near the exhaust to control the activity lost 
(see Figure 5.7). 
The choice of the solvent used to dissolve the chemical precursor may affect the final 
yield as it has the function of retaining the [11C]methylation agent but can also bring 
potential impurities associated to it (e.g., cyclohexanone needs to be previously dried 
with MgSO4
(101)). So we tested some of the most common solvents used in 
[11C]radiolabelling (MEK, DMF, DMSO, CH3CN and acetone) to evaluate their trapping 
capacity and the ability to enhance the reaction (for 1 minute) with the precursor. After 
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stirring 0.5 mg of 6-OH-BTA-0 with 80 µl of solvent this was immediately injected into 
the loop to avoid evaporation as a dry precursor is unable to react with [11C]CH3OTf. 
DMF is a commonly used solvent for methylation reactions with [11C]CH3I mainly due 
to its high boiling point (153º C). Nevertheless, our results showed a great escape of 
the activity from the loop resulting in an absent production of [11C]PiB. This can be 
explained by direct reaction of [11C]CH3OTf with DMF, and is by-product 
dimethylamine, forming [11C]trimethylamine which has a boiling point of 3º C. So, the 
use of DMF as solvent for our methylation with [11C]CH3OTf was promptly discarded. 
 
 
Figure 5.7. Optimum profile for [
11
C]CH3OTf trapping in the 
loop. (A) start trapping; (B) maximum trapping and beginning of 
the reaction with 6-OH-BTA-0; (C) end of the desired time of 
reaction and transfer to semi-preparative HPLC for purification 
of the crude mixture. Loop detector (solid line) and exhaust trap 
detector (dotted line) profiles are shown. 
 
When a [11C]methylation is done with [11C]CH3I, in presence of a strong base that 
catalyses the chemical precursor deprotonation, DMSO is one of the widely used 
solvents also due to its high boiling point (189º C). However, since the sulphur atom in 
DMSO is by itself a nucleophilic centre, the solvent may compete with the dissolved 
precursor when using the more reactive methylation agent [11C]CH3OTf especially if a 
base is not used(110). This reaction between DMSO and [11C]CH3OTf leading to 
[11C]methylated DMSO was potentially observed in some of the experiments that used 
these conditions for 6-OH-BTA-0 radiolabelling. Here, during the semi-preparative 
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HPLC, there is a radioactive species around the area where the DMSO peak is 
expected, as previously identified by the UV detector (see Figure 5.8). This causes, 
despite the good trapping in the loop (74.6±16.4%, n=3), a low radiolabelling yield of 
4.3±2.9% (DC) due to the [11C]methylation competition between precursor and solvent. 
This way, the use of DMSO was also set aside. 
 
 
Figure 5.8. Semi-preparative HPLC of [
11
C]PiB methylation using 
DMSO. 
 
For methylations with [11C]CH3OTf the most commonly used solvent is acetone
(111). 
However for loop reactions, where smaller amounts of solvent are employed, acetone 
is considered too volatile (boiling point of 56º C) to be used. This assumption was 
verified experimentally in our work where the loop trapping of the [11C]CH3OTf was 
about 25.5±19.9% (n=4) but then there was a good [11C]PiB reaction yield of 
18.3±7.4% (DC). 
In order to overcome this volatility problem maintaining the promising reaction yield 
achieved, Gómez-Vallejo and Llop(101) tested, with good results, a mixture of 
acetone/CH3CN (1/1) as solvent. When we also tested this solvent (firstly diluting 
6-OH-BTA-0 with acetone and then adding the remainder of CH3CN, otherwise it was 
noted the formation of a precipitate between precursor and CH3CN) we obtained a 
[11C]CH3OTf trapping efficiency of 69.3±8.6% (n=5) with a reaction yield of 22.6±4.3% 
(DC). 
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There are however a series of other less volatile ketones which may be used to dilute 
the precursor. Several [11C]methylations of various radiotracers have been made using 
MEK (boiling point of 80º C) as solvent and for this reason there was great interest to 
test it in the present work. The results obtained by diluting precursor in MEK showed a 
yield of [11C]CH3OTf trapping in the loop of 35.2±5.0% (n=3) and a following reaction 
yield of 15.5±7.9% (DC), which is in agreement with the [11C]PiB reaction yields 
reported in literature (11 to 18%) when using this solvent(97, 99). 
In summary, on our tests the use of acetone/CH3CN (1/1) showed to improve the 
trapping efficiency of [11C]CH3OTf in the loop and the [
11C]PiB reaction yield. For this 
reason all experiments described hereafter were made using this solvent. 
Another factor that can vary the yield of 6-OH-BTA-0 [11C]methylation is the quantity 
of precursor and solvent used. Considering that the precursor is always used in large 
excess on radiolabelling reactions we tested the amounts of 0.5 to 1 mg and the 
influence of solvent volumes between 80, 100 and 160 µl (see Table 5.2). The solvent 
volume was not increased too much in order to not pervert one of the main 
assumptions and advantages of the loop captive solvent method which is to use the 
lowest volume possible. The reaction time in this experimental segment was set 
constant to 1 minute. 
 
Table 5.2. Precursor dilution influence in [
11
C]PiB reaction 
yield and specific activity. 
Precursor dilution 
Yield of [
11
C]PiB 
production* 
Specific activity 
(GBq/µmol)** 
0.5 mg/80 µl (n=4) 22.6±4.3% 16.7±5.9 
1 mg/80 µl (n=3) 21.1±4.2% 20.4±6.6 
1 mg/100 µl (n=3) 19.0±2.1% 17.2±1.5 
1 mg/160 µl (n=3) 15.1±3.1% 17.3±0.7 
  *DC and **End of synthesis (EOS) values 
 
Analyzing this results we can infer that lower volumes of acetone/CH3CN (1/1) leads 
to better yields of [11C]PiB production. This may be due to the fact that by reducing 
solvent volume we are also reducing potential impurities contained in them, particularly 
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traces of H2O, which will limit the production of by-products like [
11C]methanol. With the 
dilution 1 mg/80 µl it was achieved the best results for SA. 
Finally, and using the best conditions of 1 mg of 6-OH-BTA-0 diluted in 80 µl of 
acetone/CH3CN (1/1), we tested the influence of reaction time in final [
11C]PiB yield and 
in the obtained SA (see Table 5.3). 
 
Table 5.3. Reaction time influence in [
11
C]PiB production yield 
and specific activity. 
Reaction time 
(minutes) 
Yield of [
11
C]PiB production* Specific activity 
(GBq/µmol)** 
1 (n=3) 21.1±4.2% 20.4±6.6 
2 (n=4) 23.5±6.8% 27.2±4.5 
3 (n=4) 15.7±4.1% 20.3±0.8 
4 (n=3) 18.4±3.9% 16.2±1.5 
  *DC and ** EOS values 
 
Through the optimization of the solvent, precursor dilution and reaction time it was 
possible to identify that the reaction conditions which lead to better results in the 
commercial system used in this work were: 1 mg of 6-OH-BTA-0, diluted firstly in 40 µl 
of acetone and then completed with more 40 µl of CH3CN, allowed to react with 
[11C]CH3OTf at room temperature during 2 minutes (see Table 5.4). 
 
 Table 5.4. Optimal [
11
C]PiB reaction conditions and comparison with several authors. 
Reaction 
temperature 
Reaction 
time 
(minutes) 
Precursor 
quantity 
(mg) 
Solvent 
(volume) 
Yield of 
[
11
C]PiB 
production 
Specific 
activity 
(GBq/µmol) 
Reference 
Room 
temperature 
2 1.0 
Acetone/CH3CN 
(80 µl) 
23.5±6.8% 27.2±4.5 --- 
60º C 2 0.5 
Acetone 
(400 µl) 
14.5% 0.037 Mikhno et al.
(98)
 
80º C 1 1.0 MEK (2 ml) 18% 9.3 Cheung and Ho
(99)
 
Room 
temperature 
1 1.0 
Cyclohexanone 
(80 µl) 
13-15% 20-60 Verdurand et al.
(104)
 
20º C 1 0.4 MEK (250 µl) 11-16% 30-60 Wilson et al.
(97)
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However, to obtain a high chemical and radiochemical purity [11C]PiB solution with the 
suitable characteristics for human i.v. administration, it is also mandatory to carry out 
an optimization of the commercial reformulation system (ReFORM-PlusTM) installed 
after semi-preparative HPLC purification process, as will be discussed below. 
 
5.4 Final purified saline solution of [11C]PiB 
Through the semi-preparative HPLC it was possible to carry out a purification of the 
compound of interest, in this case [11C]PiB (rt of 6.88±0.44 min), by collecting it 
separately from other species in the mixture (see Figure 5.9) and trapping it in a C18 
silica-based bonded phase cartridge, monitored with a radiometric detector, installed in 
a disposable 5-way stopcock manifold at ReFORM-PlusTM (see Figure 4.3). 
 
   
Figure 5.9. Semi-preparative HPLC for purification of [
11
C]PiB. (A) start of peak collection; (B) stop 
peak collection and beginning of reformulation. 
 
Not surprisingly high quantities of [11C]CH3OH were produced in parallel with [
11C]PiB 
since [11C]CH3OTf is extremely sensitive to water leading preferentially to the 
radiosynthesis of this radiochemical impurity. The amount of this impurity can be 
controlled with the care of keeping all system lines dry. 
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Sep-Pak C18 cartridges were designed to adsorb hydrophobe analytes from aqueous 
solutions ensuring reproducible separations. The octanol-buffer partition coefficient 
(log P) is a measure of the lipophilicity of a compound (log P >0 characterize 
hydrophobic substances soluble in a lipid phase, while log P <0 typifies polar 
compounds soluble in a water phase) and since [11C]PiB log P is 2.48±0.063(112) it has 
the physicochemical characteristics to suffer retention in that SPE system. 
However, by passing the collected fraction directly from the HPLC to the C18 SPE 
cartridge with a flow rate of 9 ml/min, as intended in the original commercial system, we 
observed that the retention in the column was very poor which caused heavy losses in 
the final amount of the obtained radiotracer. So a change has been implemented in the 
system to make the collected fraction to be diluted first in a vial with 10-15 ml of WFI 
and only then slowly passed through the SPE cartridge (see Figure 5.10). By doing this 
procedure the losses of radiotracer were considered insignificant since practically all 
the monitored activity was retained in any of the columns tested. The difference 
between C18 Plus Light (130 mg, 55-105 µm), C18 Plus Short (360 mg, 55-105 µm) 
and tC18 Plus Long (900 mg, 37-55 µm) Sep-Pak is in the quantity of silica per 
cartridge and its particle size. These particularities will affect the absorptive capacity of 
each one and so the volume of eluent needed. 
 
 
Figure 5.10. SPE C18 cartridge profile during [
11
C]PiB purification. (A) collection of 
[
11
C]PiB peak (see Figure 5.9) to the dilution vial; (B) start of trapping in C18 sep-pak 
cartridge; (C) maximum [
11
C]PiB trapping and washing with WFI; (D) elution with a 
volume of ethanol and beginning of collection at final product vial; (E) final washing of 
the cartridge and dilution with NaCl 0.9%. 
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To better wash each column from CH3CN and NH4HCO2, coming from the mobile 
phase where [11C]PiB was diluted, they were eluted with 10-15 ml of WFI. Thus, in the 
C18 columns, we only expect to retain the radiotracer and minor trace amounts of 
CH3CN (which will be quantified by GC to ensure that the achieved values are within 
the limits allowed for i.v. administration). 
To recover the product trapped it is necessary to elute the C18 cartridge with a certain 
volume of ethanol collecting it on the final product vial. However, since ethanol will 
carry out [11C]PiB to the final injectable solution thus becoming a part of it, it is 
necessary to optimize this process by selecting the cartridge which requires the lower 
volume of this solvent to be fully eluted with minimum losses of the radiotracer. This 
way, the tested cartridge that had the best result was C18 Plus Light. This SPE column 
proved to be completely eluted with a volume of 0.3-0.5 ml, while tC18 Plus Long and 
C18 Plus Short need an amount between 0.6 and 1.0 ml to achieve the same results. 
After reaching the final product vial, ethanol containing [11C]PiB is diluted by 9 ml of 
NaCl 0.9% (that also passes through C18 column to wash the trace amount of 
radioactivity still remaining there) to turn the solution in a physiologically injectable one. 
Immediately before any solution enter into the final product vial, it is purified by a 
sterilizing disposable filter unit to remove microorganisms, particles, precipitates and 
other undissolved components larger than 0.22 μm. This procedure is indispensable for 
non-pyrogenic i.v. administration solutions prepared in situ and therefore two kinds of 
sterilizing filters (Millex®-GS for aqueous solutions and Millex®-GV for aqueous or mild 
organic solutions) were tested. By passing the same [11C]PiB solution through the two 
filters it was observed that Millex®-GV is the most appropriate for purification and 
sterilization of the final product being suitable for hydrophobic compounds since it only 
retains 8.9±2.9% of the final solution activity while in Millex®-GS there are higher losses 
as it retains 20.8±18.1%. After filtration of the final solution it has to be done a BPT to 
verify filters integrity. 
In a set of 12 radiolabelling and reformulation experiments, that were made after 
defining the optimal conditions (see Table 5.5), it was obtained an absolute [11C]PiB 
reaction yield of 23.5±6.8% (after sterile filtration), referred to [11C]CH3I (DC), with a SA 
of 27.6±4.1 GBq/µmol. The observed formation of the non collected 6-[11C]MeO-BTA-0 
specie was about 5.9±1,6% and, at EOS, 3.2±1.2 GBq of pure [11C]PiB were obtained 
with a total synthesis time between 25 to 30 minutes. Therefore, the values of SA 
reached in this project, as well as the yields of [11C]PiB production, are higher or 
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amongst those described in literature that also uses “wet method” for producing the 
primary radioactive precursor [11C]CH3I (see Table 5.4). 
The consideration of SA, as already described, is particularly important in the 
production of a radiotracer and its degree must be addressed depending on the nature 
of the molecular target in study. According to a recent paper from Manook et al.(113) a 
value between 11.1 and 14.8 GBq/µmol proved to be sufficient for routine applications 
in [11C]PiB molecular imaging of AD patients. So, after quality assurance, the 
synthesised product has all the conditions to be used in human clinical assays. 
 
5.5 Assurance of the final product quality 
Intravenous administration of a radiotracer must comply with both radiation and 
pharmaceutical standards not only to ensure safety but also to establish its efficiency 
since the in vivo behaviour is dependent on high levels of radionuclidic, radiochemical 
and chemical purity. In addition, injectable solutions must also satisfy other standards 
of sterility, apyrogenicity, osmolarity and pH to ensure the safe administration in 
humans. These parameters are detected and quantified using analytical techniques 
according to the general radiopharmaceutical preparations monograph of Ph. Eur. 
So far, not a single complete process of synthesis and reformulation of [11C]PiB failed 
and in all cases a visual inspection of the final solution proved that it meets the 
organoleptic characteristics of being clear, colourless and free of particulate matter. 
From the set of 12 synthesis and reformulation under the optimized conditions, all the 
obtained solutions complied with the parameters of quality assurance (see Table 5.5). 
After measurement of the EOS activity in a dose calibrator a small sample was taken to 
proceed to the pH test. The average pH of the solutions was 5.8±0.7 which is in 
agreement with the Ph. Eur. referenced range for radiopharmaceutical injection 
solutions (4.5-8.5). 
Radionuclidic purity, defined as the percentage of the radioactivity of the required 
radionuclide to the total radioactivity of the solution(114), as well as its identity were 
assessed by t1/2. The rate at which a radioactive isotope decays is measured in half-life, 
a particular physical property of each one that allows their identification. A deviation of 
more than 5% of the expected value (20.4 minutes for 11C) may indicate the presence 
of other radioisotopes and the performance of several measurements over time of the 
activity of samples taken from each [11C]PiB synthesized showed always a t1/2 within 
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this range. This is important to ensure that will be prevented an unnecessary irradiation 
of the patient and to avoid a possible degradation of image quality. 
 
Table 5.5. Results obtained with [
11
C]PiB radiolabellings. 
 
Activity 
EOS (GBq) 
Specific activity 
(GBq/µmol) 
[CH3CN] 
(mg/10ml) 
pH 
t1/2 
(min) 
Chemical 
purity (%) 
Radiochemical 
purity (%) 
        
1 0.4 27.4 2.2 5.5 20.3 99.4 97.1 
2 3.5 23.9 1.0 5.3 20.4 99.4 99.5 
3 4.7 31.7 0.9 5.2 21.2 99.7 99.4 
4 3.8 22.8 1.1 5.8 20.5 99.4 95.2 
5 4.1 32.0 0.4 5.6 20.6 99.4 99.1 
6 4.2 30.0 1.3 5.8 20.4 98.7 99.4 
7 2.9 28.1 1.1 5.6 20.6 99.1 98.4 
8 3.9 26.0 1.5 5.3 20.6 99.7 98.5 
9 3.6 23.9 0.9 5.5 20.4 98.1 95.1 
10 3.2 21.3 1.5 5.8 19.7 99.6 96.2 
11 1.4 34.5 3.6 7.6 20.4 97.6 95.4 
12 3.2 30.0 2.8 6.4 20.4 99.5 98.1 
 3.2±1.2 27.6±4.1 1.6±0.9 5.8±0.7 20.5±0.4 99.1±0.7 97.6±1.8 
 
Levels  of  residual  solvents  in  final  solutions  were  quantified  by  GC/FID  
(see Figure 5.11). Since [11C]PiB injection vehicle is 5% ethanol (95% NaCl 0.9%) and 
acetonitrile forms part of the mobile phase these are the two possible organic volatile 
impurities that may be present in an i.v. radiotracer dose within the limits described at 
Ph. Eur. (ethanol ≤50 mg/10 ml; CH3CN ≤4.1 mg/10 ml). 
All CH3CN values obtained with the final solution were below the limit of 4.1 mg/10 ml 
which means that, assuming a maximum injection volume of 10 ml, 4.1mg were 
injected in a standard 70 kg human. This would result in a dose of about 60 µg/kg well 
below the LD50 (a standardized measure for expressing and comparing the toxicity of 
chemicals defined as any dose that kills 50% of the test animals) for CH3CN 
administered i.v. in rats (1.68 mg/kg(115)). With regard to ethanol, the maximum amount 
used to elute C18 Plus Light cartridge was 0.5 ml or 0.4 g (assuming a density of 
0.8 g/ml at room temperature). This means that no more than 6 mg/kg are injected in a 
standard 70 kg human, which is also well below the LD50 for ethanol administered i.v. in 
rats (1440 mg/kg(116)). So, even knowing that ethanol represents 5% of total [11C]PiB 
final solution there is no risk in its administration to humans. In fact our 5% of ethanol 
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are below the 10% limit used in several radiopharmaceutical centres to enhance the 
solubility of highly lipophilic radiotracers or to decrease their adsorption to vials, 
membrane filters, and syringes(117). As a precaution to the potential side effects of 
ethanol (pain and haemolysis) the solution should be injected slowly, which decreases 
the concentration at the site of injection by rapid mixing with large volumes of blood. 
 
 
Figure 5.11. Gas chromatography of the final [
11
C]PiB i.v. solution. 
 
For quantifying chemical and radiochemical purity we used a HPLC with a UV and 
radiometric detector. Although retention time of each chemical species have been 
previously identified by injection of cold standards, it was also injected into the HPLC 
an unpurified reaction crude mixture to ensure that each one would be effectively 
distinguished in this analytical method (see  Figure 5.12). 
Radiochemical purity is defined as the percentage of the radionuclide present in the 
desired chemical form whereas chemical purity refers to the proportion of the solution 
that is in a specific chemical form, regardless of the presence of radioactivity(114). 
Radiochemical species are chromatographly separated based on differences in 
chemical characteristics, then the radioactivity associated with each chemical species 
is assayed using a radiometric detector. Generally chemical impurities in radiotracer 
preparations only are problematic if they are toxic, can cause undesired interactions or 
modify the physiological process under study. That is why, although radiochemical 
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purity for i.v. doses typically must be higher than 95%, there are currently no chemical 
purity requirements for release of radiotracers for clinical use(102). 
 
 
  Figure 5.12. Analytical HPLC of [
11
C]PiB solution before purification. 
 
All [11C]PiB final solutions controlled have revealed a level of radiochemical purity 
≥98% and chemical purity >95% (see Table 5.5), as can be seen on Figure 5.13 by the 
presence of a single species in a typical chromatogram before i.v. administration. 
Radiochemical identity of [11C]PiB can be confirmed by comparison of its rt with the one 
obtained with the cold reference standard or by co-injection in the analytical HPLC. 
 
 
Figure 5.13. Analytical HPLC of the final [
11
C]PiB i.v. solution. 
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It should be noted that radiochemical purity may not be constant since it has been 
recognized that aqueous solutions of radiolabelled compounds tend to decompose 
when exposed to high temperatures, when comes into contact with the final vial rubber 
stopper components or over time via radiolysis caused by the interaction of their own 
radiation with water(114, 118). However, a sample of our product placed in contact with the 
butyl rubber stopper showed, after 3 hours, to continue with a radiochemical purity 
higher than 98%. The same happened when it was submitted to an autoclaving 
process that reaches a temperature between 131.5º-132.5º C during 2 minutes, which 
proved the great stability of this radiotracer. A study over time also demonstrated that 
the radiotracer is stable at least 4 hours after synthesis at room temperature, having a 
radiochemical purity above 97% (see Figure 5.14). 
 
  
Figure 5.14. [
11
C]PiB final solution stability over time. 
 
The intensity of radiolysis is extremely dependent on the amount of final activity 
obtained and on the radiotracer SA(114, 118). The value of this latter parameter is 
calculated using a reference curve (see Figure 5.3) and the known total activity and 
final volume of [11C]PiB solution. The achieved SA (EOS) is in the range of 27.6±4.1 
GBq/µmol which, as already discussed above, is suitable for human molecular imaging 
studies. 
Through SA and total EOS activity is possible to estimate the number of moles and 
consequently the mass of PiB present in solution (MM = 256 g/mol). By this way we 
can arrive to an important parameter to be taken into account in injectable solutions, 
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the osmolarity, which measures the number of moles of a chemical compound per litre 
that contributes to osmotic pressure. This process is of vital importance once cell 
membranes are selective according to the solutes found in circulation. The osmolarity 
of the i.v. agents should also be appropriate for blood in order to not cause haemolysis 
and, for this reason, it should be taken into account the reference value of NaCl 0.9% 
osmolarity (approx. 308 mOsmol/liter). 
A theoretical osmolarity concentration can be calculated for [11C]PiB solution using the 
equation mOsmol/liter = [(mass (g)/volume (l)) / MM (g/mol)] x (nº of species x 1000). 
Considering the mean values of total activity EOS (3.2 GBq) and SA (27.6 GBq/µmol), 
knowing that our final volume is 10 ml (0.5 ml of ethanol and 9.5 ml of NaCl 0.9%) and 
since there is no dissociation of the compound it was reached a theoretical value of 
approximately 0.012 mOsmol/liter for [11C]PiB solution. So, the contribution of this value 
would not significantly affect the isotonicity and osmolarity of the principal vehicle for 
injection (NaCl 0.9%) since ethanol is not taken into account as it freely diffuses 
through the cell membrane.  
Sterile filter integrity test also gives some assurances about the quality of the solution 
injected and later tests for bacterial endotoxins (LAL test) always demonstrated that it 
had less than 17.5 EU/ml, as specified in Ph. Eur. However, because short lived 
radiotracers cannot be tested for all pharmaceutical parameters prior to administration, 
the entire process must be monitored and documented. 
In conclusion, the whole procedure from the release of [11C]CO2 by cyclotron to final 
i.v. administration of the radiotracer, including quality control, is performed in about 45 
minutes. This time is clearly compatible with radioisotope t1/2 avoiding excessive losses 
in its radioactivity. 
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6. Final considerations 
 
Due to the socio-economic impact and the alarming increase in its incidence in 
modern societies, largely because the demographic transition that has been observed 
in recent decades with repercussions in population aging, AD has been the target of a 
huge scientific investment for its understanding. Constantly new findings are being 
revealed that lead to a better understanding of this dementia, such as a recent study 
that provided evidences that Aβ protein aggregates can behave as prions (infectious 
agent composed by abnormal proteins) that cause AD(119) or another one that showed 
that a mutation in the APP A673T gene confers a protective effect against it(120). 
In the absence of a curative or preventive treatment for AD, an early diagnosis allows 
a non-pharmacological and pharmacological intervention focusing in relieving 
symptoms and preserving physical skills, with real gains in quality of life. So, highly 
specific and sensitive biomarkers are of great value to assess an early diagnosis that 
could result in therapeutic efficacy. However, initial identification of typical AD 
molecular changes generally involves techniques that are not widely disseminated and 
that, in some cases, are also complex and invasive. 
In an attempt to counter these assumptions efforts were made in the area of 
Molecular Imaging that led to the development of [11C]PiB, a promising PET agent that 
has been widely used since the beginning of the XXI century. Its efficiency for the early 
detection of Aβ, characteristic of AD, and differentiation from other dementias continues 
to be reiterated by recent studies that support the idea that this radiotracer is 
particularly useful as a diagnostic tool for distinguish AD from prodromal or MCI stages 
and also could be useful for the discovery of novel disease-related properties of 
amyloid(121). The interest in the use of [11C]PiB has been such that the limits on its use 
exceeded the boundaries of AD since, for example, there are recent data that suggest 
its potential in the quantification of demyelination in multiple sclerosis patients(122). 
Despite the affinity, specificity and sensitivity demonstrated for earlier detection of Aβ 
plaques, due to the limited half-life, [11C]PiB can only be used at sites that have the 
unavoidable conditions for its production, including a radiochemistry laboratory with 
cyclotron, and detection by PET, which has hindered the access of the general 
population for this diagnostic exam. By having all these conditions, ICNAS made a 
strong commitment to establish an automated and reproducible process for 
radiolabelling, purification and reformulation of [11C]PiB using a system composed by 
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commercial synthesis modules (Bioscan Inc.) in order to obtain a sterile and 
pyrogen-free injectable solution to be used in humans. The advantages of using 
automated synthesis modules over more traditional approaches are related to a more 
reliable reproducibility of the process, to a safer and facilitated handling of high 
radioactivity doses by eliminating manual operations and with the regulatory 
compliance with pharmaceutical manufacturing practices. 
The used captive solvent [11C]methylation method have proved to be extremely 
effective for [11C]PiB radiosynthesis presenting, after optimization, an absolute reaction 
yield of 23.5±6.8%, a SA of 27.64.1 GBq/µmol, and a radiochemical purity of at least 
98%. These aspects were confirmed in vivo by human clinical assays where, 
confronting healthy persons with patients whose history refers to a suspected AD, it 
was observed a hiperfixation in the characteristic regions of this dementia 
(frontoparietal lobes) and very low uptake in control cases (see Figure 6.1). 
Despite its effectiveness, one of the major drawbacks of the method used is that 
radiotracers coexist with a reasonable high quantity of the non-radioactive species, 
leading to limited specific activities. In this work we tried to reduce to the maximum 
possible the formation of non-radioactive species due to the presence and 
incorporation of atmospheric [12C]CO2 before treatment with HI. However, other factors 
as increasing cyclotron target gas purity (e.g., through filtration), the use of a more 
concentrated LiAlH4/THF solution (1 M) or, although more difficult because it requires 
quite different equipment, a [11C]CH3I production by the “gas phase” method, may be 
procedures that could be tested in future to increase SA. 
The performed optimization in [11C]PiB radiosynthesis also served to prepare all the 
system and refine techniques that could lead to the availability of other carbon-11 
radiotracers for clinical assays in ICNAS (e.g., [11C]PK11195, [11C]raclopride or 
[11C]flumazenil) or for the development of new radiolabelled molecules. 
Regardless of compelling results with [11C]PIB the short half-life limits the use of 
[11C]molecules. This emphasizes the need for [18F]molecules, with longer half-life, to 
implement a broader Aβ PET imaging. The radiotracers for AD that have been 
developed to date have focused primarily on the affinity for the Aβ deposits. However it 
is known that there are several subspecies of Aβ whose importance is still not fully 
known since there are cases of dementia symptoms without the associated plaques 
and there are also cases in which the presence of these are not manifested 
symptomatically. 
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Figure 6.1. [
11
C]PiB amyloid binding to the brain of an AD (A) and healthy (B) cases. Red indicates 
high, green medium and blue low [
11
C]PiB retention. (Images courtesy of ICNAS) 
B 
A 
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A challenge that has been stimulating the radiochemical community, involves the 
synthesis of radiotracers that allow visualizing in vivo the different Aβ subspecies and 
its expression in the brain with and without pathology. Thus, amyloid imaging may 
become more and more a sensitive tool for the early detection of AD. This could assist 
in the selection of patients for anti-amyloid therapies and help to better understand the 
underlying pathological mechanisms and progression of this dementia. 
Beyond the development of new specific radiotracers it is also important to recognize 
the utility of the new hybrid systems, in particular PET/MRI, since these add a 
tremendous spatial resolution to molecular imaging allowing the revelation of critical 
information regarding to early changes in the anatomy and physiology of dementia. 
Together, the development of even more specific radiotracers and the tuning of the 
detection technology, may lead to a change in the paradigm of the early diagnosis and 
potential treatment of Alzheimer's disease. The truth is that, more than ever, this 
pathology is on the scientific worldwide agenda and we are heading for a broader 
comprehension of its very primordial molecular mechanisms. 
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